

## Enantio- and Diastereoselective Syntheses of 3-Hydroxypiperidines through Iridium-Catalyzed Allylic Substitution

Johannes Hoecker,<sup>[a][‡][#]</sup> Georg C. Rudolf,<sup>[a][‡‡][#]</sup> Florian Bächle,<sup>[a][‡]</sup> Steffen Fleischer,<sup>[a][111]</sup> Benjamin D. Lindner,<sup>[a]</sup> and Günter Helmchen\*<sup>[a]</sup>

Keywords: Nitrogen heterocycles / Lactams / Alkaloids / Azasugars / Iridium / Amination / Epoxidation

Stereoselective syntheses of 3-hydroxypiperidines have been developed. Key intermediates are N-protected allylamines that are prepared by an enantioselective iridium-catalyzed allylic amination. A subsequent catch and release procedure that involves an epoxidation and base-mediated elimination

Introduction

The 3-hydroxypiperidine unit is a chemically and biologically important structural motif that is found in natural products, particularly alkaloids<sup>[1]</sup> and azasugars.<sup>[2]</sup> It can also be found in a number of pharmaceutically relevant small molecules. Typical examples (see Figure 1) of 3-hydroxypiperidines and their derivatives are the neurokinin NK-1 receptor antagonist (+)-L-733.060.<sup>[3]</sup> prosopinine, which is a member of the Cassia and Prosopis families of alkaloids,<sup>[4]</sup> and the azasugar miglustat (Zavesca), a drug used for the treatment of Gauchers' disease.<sup>[5]</sup>

Given their interesting biological properties, the stereoselective syntheses of 3-hydroxypiperidines have been pursued with some intensity.<sup>[6]</sup> The preferred targets have been azasugars, which are mostly synthesized through carbohydratebased routes.<sup>[7]</sup> For the large group of monohydroxypiperidines, a great variety of diastereoselective total syntheses have been developed. Chirality was mostly introduced by using a chiral pool approach or with the help of stoichiometric chiral auxiliaries.<sup>[6]</sup> Asymmetric catalysis has only

- Homepage: http://www.uni-heidelberg.de/institute/fak12/OC/ helmch/
- [‡] Present address: Organisch-Chemisches Departement der Universität Basel.
  - St. Johanns-Ring 19, 4056 Basel, Switzerland
- [‡‡]Present address: Fakultät für Chemie, Technische Universität München,
- Lichtenbergstraße 4, 85747 Garching, Germany [‡‡‡]Present address: Leibniz-Institut für Katalyse e.V. an der Universität Rostock
- Albert-Einstein-Straße 29a, 18059 Rostock, Germany
- [#]These authors contributed equally.
- Supporting information for this article is available on the WWW under http://dx.doi.org/10.1002/ejoc.201300445.

yields  $\delta$ -lactams that are suitably functionalized to prepare biologically active 3-hydroxypiperidines. In addition, applications of this method to the total syntheses of deoxymannojirimycin, D-erythro-sphingosine, and chiral building blocks of interest for medicinal chemistry are described.



Figure 1. Examples of 3-hydroxypiperidines that are found among alkaloids and drugs.

been applied to a comparatively small number of syntheses.<sup>[8]</sup>

In the course of our work on the stereoselective syntheses of piperidine and pyrrolidine alkaloids,<sup>[9]</sup> we have developed an enantio- and diastereoselective route to  $\alpha$ ,  $\beta$ -unsaturated hydroxylactams **D** and related cyclohexenones that is a combination of an iridium-catalyzed asymmetric allylic substitution reaction,<sup>[10]</sup> a ring-closing metathesis (RCM), and a catch and release methodology that involves an epox-



Scheme 1. Strategy for the enantio- and diastereoselective synthesis of 3-hydroxypiperidines ( $\Sigma$  = protecting group, LG = leaving group).

WILEY 1

ONI INF LIBRARY

<sup>[</sup>a] Organisch-Chemisches Institut der Universität Heidelberg, Im Neuenheimer Feld 270, 69120 Heidelberg, Germany Fax: +49-6221-544205 E-mail: G.Helmchen@oci.uni-heidelberg.de

idation and elimination reaction (see Scheme 1).<sup>[11]</sup> Knight et al. have developed a route to compounds of type **B** that employs a Pd-catalyzed decarboxylative carbonylation of 5-vinyloxazolidin-2-ones, which are derived from amino acids, that is, an exchiral pool approach.<sup>[12]</sup> Independence of our approach from amino acids with their limited set of substituents **R** allows to widen the range of compounds of types **B**–**D**. A further variety of targets can be synthesized with this approach as will be shown below.

#### **Results and Discussion**

The lactams **5a–5d** (see Schemes 2 and 3) were synthesized by two different routes, that is, either by allylic amination<sup>[13]</sup> and a subsequent N-acylation to give **5a–5c** (see Scheme 2) or by allylic amination with an amide,<sup>[14]</sup> in this case with *N*,*N*-diacylamine **2d**,<sup>[15]</sup> followed by deprotonation/reprotonation to give **5d** (see Scheme 3). The direct amination with *N*-Boc-but-3-enamide (Boc = *tert*-butoxycarbonyl) could not be accomplished because of the competing isomerization of the double bond under basic conditions to give *N*-boc-but-2-enamide.



Scheme 2. *Reagents and conditions:* (a)  $[Ir(COD)Cl]_2$  (2 mol-%, COD = 1,5-cyclooctadiene), L1 or L2 (4 mol-%), 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD), tetrahydrofuran (THF), 45 °C; **3a: L2**, 89%, b/l, 93:7, 97% *ee*; **3b: L2**, 77%, b/l, 97:3, 98% *ee*; **3c: L1**, 70%, b/l, 81:19, 96% *ee*; (b) But-3-enoic acid, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, DCC, 0 °C to room temp.; **4a**: 90%; **4b**: 95%; **4c**: 92%; (c) Grubbs I or II, CH<sub>2</sub>Cl<sub>2</sub>, reflux; **5a**: 93%; **5b**: 91%; **5c**: 100%.

The chiral phosphoramidite ligands L1 and L2<sup>[13e]</sup> were used for the allylic amination reactions (see Scheme 2). The reactions of the amines [BnNH<sub>2</sub> or PMBNH<sub>2</sub> (PMB = *para*-methoxybenzyl)] with carbonates **1a**-**1c** proceeded with high enantio- and regioselectivity [**3a**: 89%, branched (b)/linear (1), 93:7, 97%*ee*; **3b**: 77%, b/l, 97:3, 98%*ee*; **3c**: 70%, b/l, 81:19, 96%*ee*], essentially as reported for **3a**,<sup>[16]</sup> **3b**,<sup>[13a]</sup> and **3c**.<sup>[13f]</sup> The amines were acylated by using Steglich's method with but-3-enoic acid, 4-(dimethylamino)pyridine (DMAP), and *N*,*N'*-dicyclohexylcarbodiimide (DCC) to give amides **4** in 90–95% yield. Finally, the ring closure of dienes **4a**-**4c** was carried out by employing a ring-closing metathesis in good to excellent yields.



Scheme 3. *Reagents and conditions:* (a)  $[Ir(COD)Cl]_2$ , L2, TBD, THF, 45 °C, 87%, b/l, 93:7, 98% *ee*; (b) KHMDS, THF/DMPU, -78 °C, then dimethyl malonate, -78 °C, 85%; (c) Grubbs I, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 73%.

Carbamate **3d** (see Scheme 3) was prepared in 87% yield (b/l, 93:7, 98%*ee*) by treating carbonate **1d** with pronucleophile **2d** under salt-free conditions as previously reported.<sup>[15]</sup> The shift of the double bond to the terminal position was accomplished in 85% yield by deprotonation at -78 °C with potassium hexamethyldisilazide (KHMDS) in THF followed by the addition of 1,3-dimethyltetrahydropyrimidin-2(1*H*)-one (DMPU) and dimethyl malonate as a proton source. A subsequent ring closure to give lactam **5d** was carried out through a ring-closing metathesis as described above for **5a–5c**.

With 5a-5d available, we investigated the catch and release procedure to yield  $\alpha,\beta$ -unsaturated hydroxylactam building blocks 6a-6d (see Table 1). For the epoxidation, we used the reaction conditions that were reported by Knight et al. for their synthesis of D-mannolactam, that is, Oxone (2 KHSO<sub>5</sub>·KHSO<sub>4</sub>·K<sub>2</sub>SO<sub>4</sub>) in a mixture of a saturated aqueous NaHCO<sub>3</sub> solution and acetone at room temperature (see Table 1, Entry 1).<sup>[11c,17]</sup> In the case of 5 in which  $R = CH_2OTBS$  (TBS = *tert*-butyldimethylsilyl) and  $\Sigma = H$ , these authors obtained a trans/cis diastereoselectivity of 4.1:1 (see Table 1, Entry 1). The diastereoselectivities with the N-protected amides were generally high, even in case of **5a** with R = Me (see Table 1, Entry 3). With the sterically more demanding substituents (i.e., 5c and 5d, see Table 1, Entries 5 and 6), the trans isomer was produced almost exclusively.[18]

The synthesis of azasugar 1-deoxymannojirimycin (11) was carried out using chiral building block **6c** as the starting material (see Scheme 4). A similar synthesis was reported by Knight et al.<sup>[11c]</sup> The reaction of **6c** with NaH/ benzyl bromide/NBu<sub>4</sub>I gave **7** in excellent yield. Dihydroxylation under standard conditions (OsO<sub>4</sub> in *tert*-butanol with water and pyridine as additives) gave diastereomerically pure **8** in 74% yield. The reduction of **8** with LiAlH<sub>4</sub> furnished piperidine derivative **9** in 86% yield. The deprotection of **9** was effected by treatment with acetic acid followed by a catalytic hydrogenation reaction to give the azasugar 1-deoxymannojirimycin, which was isolated as its hydrochloride **11**•HCl in 47% yield from **8**.



Table 1. Epoxidation/elimination of lactams 5a-5d.



6	5d	Oxone	>50:1 <sup>[h]</sup>	90
5	ent-5c	Oxone	>50:1 <sup>[h]</sup>	85
4	5b	Oxone	93:7	61
3	5a	Oxone <sup>[g]</sup>	92:8	68
2	5a	m-CPBA <sup>[e]</sup>	82:18	_[f]
1	21	Oxone	4.1.1	90

[a] See GP4 in the Exp. Section. [b] Regioselectivity was determined by <sup>1</sup>H NMR analysis of the crude allylic alcohol or by isolation of the regioisomers. [c] Isolated yield of the mixture of both regioisomers. [d] Starting material is **5** with R = CH<sub>2</sub>OTBS and  $\Sigma$  = H (see ref.<sup>[11c]</sup>). [e] *m*-CPBA = *meta*-chloroperoxybenzoic acid. [f] The yield was not determined. [g] Epoxidation was performed at 0 °C. [h] The *cis* isomer was not detected by <sup>1</sup>H NMR spectroscopy.



Scheme 4. *Reagents and conditions:* (a) NaH (2.5 equiv.), NBu<sub>4</sub>I, PhCH<sub>2</sub>Br, THF, 0 °C to room temp., 97%; (b) OsO<sub>4</sub>, *N*-methylmorpholine-*N*-oxide (NMO), *t*BuOH/H<sub>2</sub>O/pyridine, room temp., 74%; (c) LiAlH<sub>4</sub>, Et<sub>2</sub>O, room temp., 86%; (d) AcOH, reflux, 79%; (e) Pd(OH)<sub>2</sub>/C, H<sub>2</sub>, room temp., 69%.

To access *cis*-configured hydroxypiperidines, which are also encountered in pharmaceuticals and alkaloids (cf. Figure 1), the inversion of the relative configuration at C-3 of the *trans*-lactams **6** was studied and accomplished. Catalytic hydrogenation gave lactams **12** (see Scheme 5), which were oxidized by treatment with Dess-Martin periodinane (DMP) or under Swern conditions to give ketones **13a** and **13b**, respectively. The potential racemization was of concern at this stage, therefore, the *ee* values of the ketones were carefully determined by HPLC analysis. The values were determined to be 96.5 and 98% *ee*, respectively, which demonstrated that the degree of racemization was small. Reduction of ketones **13** with a large excess amount of NaBH<sub>4</sub><sup>[19]</sup> in methanol at room temp. furnished the *cis*hydroxypiperidines *cis*-**12a** and *cis*-**12b** in >80% yield over the two steps with diastereoselectivities of 92:8 and >99:1, respectively. The lactam *cis*-12b has been used by Huang and co-workers in the synthesis of the neurokinin 1 antagonist (+)-L-733.060 (cf. Figure 1).<sup>[20]</sup>



Scheme 5. *Reagents and conditions:* (a) for *trans*-12a: Pd/C, H<sub>2</sub>, EtOAc, room temp.; for *trans*-12b: Rh/C, H<sub>2</sub>, EtOAc/MeOH, room temp.; (b) for 13a: DMP, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 99% (over 2 steps); for 13b: (COCl)<sub>2</sub>, dimethyl sulfoxide (DMSO), NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 84% (over 2 steps); (c) NaBH<sub>4</sub>, MeOH, room temp., *cis*-12a: 81%; *cis*-12b: 97%.

Finally, the reductive ring-opening reaction of hydroxylactams *trans*-**6** appeared of interest. This was investigated with a derivative of *trans*-**6d** to access D-*erythro*-sphingosine (**18**, see Scheme 6).<sup>[21]</sup>



Scheme 6. *Reagents and conditions:* (a) *N*-methylimidazole, I<sub>2</sub>, TBSCl, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C to room temp., 2 h, 91%; (b) CeCl<sub>3</sub>·7H<sub>2</sub>O, NaBH<sub>4</sub>, MeOH/CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, -10 °C to -2 °C, 1 h, 88% (corr.) of **15**; (c) (i) O<sub>3</sub>, MeOH/CH<sub>2</sub>Cl<sub>2</sub>, -78 °C, 5 min; (ii) Me<sub>2</sub>S, -78 °C to room temp., 76%; (d) (i) 1-phenyl-5-tetradecylsulfonyl-1*H*-tetrazole, KHMDS, dimethoxyethane (DME), -56 °C, 1 h; (ii) **16** in DME, 3 h, 64% (*E*/*Z*, 88:12); (e) trifluoroacetic acid (TFA), CH<sub>2</sub>Cl<sub>2</sub>, room temp., 2 h, 40%.

Lactam *trans*-6d was treated with TBSCl/iodine<sup>[22]</sup> to give derivative 14 in 91% yield. The ring-opening reaction of *N*-acyl- $\delta$ -lactams is commonly accomplished by using NaBH<sub>4</sub>.<sup>[23]</sup> The reductive ring-opening reaction of unsaturated lactam 14 required application under Luche conditions<sup>[24]</sup> to avoid reduction of the double bond. Initially, an *N*,*O*-acetal was formed as a byproduct, but its formation could be avoided by screening the reaction conditions. The optimized reaction involved using an excess amount of CeCl<sub>3</sub> and the reducing agent (1.5 equiv. of CeCl<sub>3</sub>, 4 equiv. of NaBH<sub>4</sub>) in combination with a reaction temperature slightly below 0 °C. Apparently, other rare earth metal salts,

for example,  $ErI_3$ , induced deprotection of the Boc group. The  $\alpha$ , $\beta$ -unsaturated hydroxylactam **15** was finally obtained in 88% yield (8% recovered starting material).

Treatment of allylic alcohol **15** with ozone gave aldehyde **16** (76% yield), which is a valuable building block for syntheses of azasugars. The alkenyl side chain of the sphingosine target was introduced by a Julia–Kocienski reaction,<sup>[25]</sup> which involved the reaction of a tetradecylsulfonyltetrazole<sup>[26]</sup> with KHMDS and then with aldehyde **16** to obtain protected sphingosine **17** in moderate yield (64%) with an *E/Z* selectivity of 88:12. Finally, deprotection gave (–)-D*erythro*-sphingosine (**18**) in 9 linear steps and 5% overall yield. Analytical data were in full agreement with those reported.<sup>[27,28]</sup>

#### Conclusions

The combination of an iridium-catalyzed allylic amination, a ring-closing metathesis, and a catch and release procedure based on epoxidation/elimination reactions allows chiral 3-hydroxypiperidines to be prepared in a highly stereoselective way. This route was applied to the total syntheses of 1-deoxymannojirimycin and D-*erythro*-sphingosine.

#### **Experimental Section**

General Methods: The <sup>1</sup>H NMR spectroscopic data were recorded at room temp. in CDCl<sub>3</sub>, unless otherwise reported, with a Bruker Avance 300 (300 MHz) or 500 (500 MHz) spectrometer. Chemical shifts are given in  $\delta$  (ppm) relative to CHCl<sub>3</sub> ( $\delta_{\rm H}$  = 7.26 ppm) or TMS ( $\delta_{\rm H}$  = 0.00 ppm). For system of numbering the atoms, see the Supporting information. The <sup>13</sup>C NMR spectroscopic data were recorded at room temp. in CDCl<sub>3</sub>, unless otherwise reported, with a Bruker Avance 300 (75 MHz) or 500 (125 MHz) spectrometer. Chemical shifts are given in  $\delta$  (ppm) relative to CDCl<sub>3</sub> [ $\delta_{\rm C}$  = 77.16 ppm (central line of the triplet)]. The abbreviations are s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), and br. (broad). The assignment of signals was confirmed by <sup>1</sup>H, <sup>1</sup>H-COSY, <sup>1</sup>H, <sup>13</sup>C-COSY, and DEPT spectroscopic data. Optical rotations were measured with a Perkin-Elmer 341 polarimeter in a thermostated cuvette (1 dm) and with a mercury lamp. HRMS were recorded with either a JEOL JMS-700 instrument (EI and FAB) or a Bruker ApexQe instrument (ESI). GC-MS chromatograms/spectra were recorded with the HP 5890 Series II Plus instrument that was coupled with the HP 5972 Mass Selective Detector. For a capillary column, the HP-1 cross-linked methyl silicone gum (25 m $\times$  $0.2 \text{ mm}, 0.33 \,\mu\text{m}$  film thickness) was employed with helium as the carrier gas. All given retention times  $(t_R)$  refer to the default temperature program [isothermal 50 °C (1 min), heating rate of 20 °C/ min (10 min), isothermal 250 °C (14 min), injector temperature: 250 °C]. Enantiomeric excess values were determined either by HPLC analysis with the HP 1090 or HP 1100 instrument or by GC with the HP 5890 instrument. For HPLC analysis, the employed Daicel columns were Chiralpak AD-H ( $250 \times 4.6 \text{ mm}$ , 5 µm) with guard cartridge AD-H ( $10 \times 4$  mm,  $5 \mu$ m) and Chiralcel OD-H  $(250 \times 4.6 \text{ mm}, 5 \mu\text{m})$  with guard cartridge OD-H  $(10 \times 4 \text{ mm},$ 5 μm). For GC analysis, a permethyl-β-cyclodextrin column from Chrompack (WCOT fused silica, Cp-cyclodextrin-B-236-M-19,  $25 \text{ m} \times 0.25 \text{ mm}$ ) was used. For preparative HPLC analysis, a Gilson-305 pump that was coupled with the Knauer UV detector 2600 and a silica gel column (ProntoSIL,  $250 \times 20$  mm, 5 m silica, 15 mL/min, 45 bar) were used. The iridium-catalyzed allylic substitutions (GP1) are described in the Supporting Information. CCDC-947888 (for **5b**), -947889 (for *trans*-**6b**), and -947890 (for *cis*-**12b**) contain the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/ data\_request/cif.

General Procedure for Acylation with 3-Butenoic Acid (GP2): A solution of 3-butenoic acid (1.2 equiv.), DMAP (20–30 mol-%), and amine 3 (1.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (0.5–0.3 M with respect to 3) at 0 °C was treated slowly with DCC (1.2 equiv.), and the resulting mixture was stirred at 0 °C (in case of 4b and 4c at room temp.) until there was complete conversion as monitored by TLC. The reaction mixture was diluted with ethyl acetate, and the suspension was filtered through a pad of Celite. Water was added, and the mixture was extracted with ethyl acetate and CH<sub>2</sub>Cl<sub>2</sub>. The combined organic layers were washed with brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was subjected to flash column chromatography on silica gel.

(-)-*N*-Benzyl-*N*-[(1*S*)-1-methylprop-2-en-1-yl]but-3-enamide (4a): GP2 was carried out using 3-butenoic acid (1.21 g, 14.0 mmol), DMAP (428 mg, 3.50 mmol), DCC (2.89 g, 14.0 mmol), and 3a (1.88 g, 11.7 mmol) in  $CH_2Cl_2$  (40 mL) for a reaction time of 3.5 h. TLC [petroleum ether/diethyl ether, 1:2;  $R_{\rm f} = 0.22$  (3a) and  $R_{\rm f} =$ 0.40 (4a); KMnO<sub>4</sub>]. The crude product was subjected to flash column chromatography on silica gel [petroleum ether/ethyl acetate, 4:1;  $R_{\rm f} = 0.18$  (4a)] to yield 4a contaminated with 3% of the isomerized product (2.41 g combined yield, 90%) as a pale yellow oil. The latter was removed in the next step (metathesis).  $[a]_{\rm D}^{20} = -82$  (c = 1.01, CHCl<sub>3</sub>); 97% ee. <sup>1</sup>H NMR (300 MHz, toluene, 90 °C):  $\delta$  =  $1.02 (d, J = 6.9 Hz, 3 H, CH_3), 2.93 (d, J = 6.2 Hz, 2 H, 2-H), 4.14$  $(d, J = 16.7 \text{ Hz}, 1 \text{ H}, \text{PhCH}_{a}\text{H}_{b}), 4.40 (d, J = 16.7 \text{ Hz}, 1 \text{ H},$ PhCH<sub>a</sub>H<sub>b</sub>), 4.71-4.84 (m, 1 H, 1'-H), 4.84-5.00 (m, 4 H, 4-H and 3'-H), 5.69 (ddd, J = 16.3, 10.4, 5.2 Hz, 1 H, 2'-H), 6.00 (ddt, J = 16.9, 10.5, 6.4 Hz, 1 H, 3-H), 6.94-7.03 (m, 1 H, Ar), 7.03-7.12 (m, 4 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, toluene, 90 °C):  $\delta$  = 17.90 (q, CH<sub>3</sub>), 39.57 (t, C-2), 47.38 (t, PhCH<sub>2</sub>), 53.83 (d, C-1'), 115.42 (t, C-3'), 116.78 (t, C-4), 127.26, 127.37, 128.83 (3 d, Ar), 133.31 (d, C-3), 139.62 (d, C-2'), 140.19 (s, Ar), 170.74 (s, C-1) ppm. GC-MS:  $t_{\rm R} = 10.6 \text{ min. HRMS}$  (EI+): calcd. for  $C_{15}H_{19}NO^+$  [M]<sup>+</sup> 229.1467; found 229.1456.

(+)-N-(4-Methoxybenzyl)-N-[(1R)-1-phenylprop-2-en-1-yl]but-3-enamide (4b): GP2 was carried out using 3-butenoic acid (1.53 g, 17.7 mmol), DMAP (360 mg, 2.95 mmol), DCC (3.66 g, 17.7 mmol), and **3b** (3.74 g, 14.8 mmol, 98%ee) in CH<sub>2</sub>Cl<sub>2</sub> (45 mL) for a reaction time of 30 min at 0 °C and 90 min at room temp. TLC [petroleum ether/ethyl acetate, 2:1;  $R_{\rm f} = 0.28$  (3b) and  $R_{\rm f} =$ 0.39 (4b); KMnO<sub>4</sub>]. The crude product was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, from 6:1 to 4:1) to give **4b** (4.51 g, 95%) as a colorless foam.  $[a]_{D}^{20}$ = +60.6 (c = 1.05, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (300 MHz, [D<sub>8</sub>]toluene, 80 °C):  $\delta$  = 2.97 (d, J = 6.2 Hz, 2 H, 2-H), 3.34 (s, 3 H, OCH<sub>3</sub>), 4.22 (d, J = 16.4 Hz, 1 H, 1''-H<sub>a</sub>), 4.39 (d, J = 16.4 Hz, 1 H, 1''-H<sub>b</sub>), 4.85–5.10 (m, 4 H, 4-H, 3'-H), 5.85–6.15 (m, 3 H, 3-H, 2'-H, 1'-H), 6.60 (d, J = 8.5 Hz, 2 H, 3'''-H), 6.86 (d, J = 8.3 Hz, 2 H, 2'''-H), 6.90-7.20 (m, 5 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, [D<sub>8</sub>]toluene, 80 °C):  $\delta$  = 40.41 (t, C-2), 49.02 (d, C-1''), 55.74 (q, OCH<sub>3</sub>), 63.07 (d, C-1'), 115.20 (d, C-3'''), 117.64, 118.92 (2d, C-3', C-4), 128.44 (d, Ar), 129.27 (d, Ar), 129.49 (d, Ar), 129.52 (d, Ar), 132.19 (s, C-1'''), 133.97, 137.35 (d, C-3, C-2'), 141.04 (s, Ph),



160.36 (s, C-4'''), 171.88 (s, C-1) ppm. GC–MS:  $t_{\rm R}$  = 16.72 min. HRMS (ESI+): calcd. for C<sub>21</sub>H<sub>24</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 322.18063; found 322.18016.

(-)-N-Benzyl-N-{(1S)-1-[(trityloxy)methyl]prop-2-en-1-yl}but-3-enamide (ent-4c): GP2 was carried out using 3-butenoic acid (90%, 1.21 g, 12.7 mmol), DMAP (358 mg, 2.93 mmol), DCC (2.62 g, 12.07 mmol), and 3c (4.10 g, 9.77 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (68 mL) for a reaction time of 25 min at 0 °C and 3 h at room temp. TLC [petroleum ether/ethyl acetate, 5:1;  $R_{\rm f} = 0.37$  (3c) and  $R_{\rm f} = 0.36$  (ent-4c); KMnO<sub>4</sub>]. The crude product was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, 7:1) to yield 4c (4.36 g, 92%) as a colorless oil.  $[a]_{D}^{20} = -32.2$  (c = 1.38, CHCl<sub>3</sub>); 94% ee. <sup>1</sup>H NMR (300 MHz, [D<sub>8</sub>]toluene, 85 °C):  $\delta$  = 3.05 (d, J = 4.5 Hz, 2 H, 2' -H), 3.32 -- 3.54 (m, 2 H, 1'' -H), 4.35 (d, J =16.6 Hz, 1 H, 1'''-H<sub>a</sub>), 4.46 (d, J = 16.7 Hz, 1 H, 1'''-H<sub>b</sub>), 4.79-5.08 (m, 5 H, 1-H, 3-H, and 4'-H), 5.67-5.91 (m, 1 H, 2-H), 5.98-6.17 (m, 1 H, 3'-H), 6.96-7.19 (m, 14 H, Ar), 7.38-7.47 (m, 6 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, [D<sub>8</sub>]toluene, 85 °C):  $\delta$  = 39.76 (t, C-2), 60.03 (d, C-1), 65.21 (t, C-1''), 88.17 [s, C(Ph)<sub>3</sub>], 117.03 (t, C-3), 117.10 (t, C-4'), 127.33, 127.54, 128.28, 128.84, 129.50 (5 d, Ar), 133.35 (d, C-3'), 135.87 (d, C-2), 139.80 (s, NCH2Ph), 144.84 (s, Ar), 171.30 (s, C-1') ppm. HRMS (ESI+): calcd. for  $C_{34}H_{34}NO_2^+$ [M + H]<sup>+</sup> 488.2584; found 488.2584.

(+)-tert-Butyl But-3-enoyl{(1R)-1-[(trityloxy)methyl]prop-2-en-1yl}carbamate (4d): Under argon, a solution of KHMDS (0.5 M in toluene, 19.50 mL, 9.75 mmol) was added over a period of 30 min through a syringe to a stirred, cooled (-78 °C) solution of carbamate 3d (2.21 g, 4.44 mmol) in dry THF (15 mL). After stirring for an additional 20 min, DMPU (11 mL) was added over a period of 20 min. The resultant orange solution was stirred for 30 min and then treated with dimethyl malonate (2.09 mL, 17.76 mmol) by dropwise addition. For this step to be successful, it was crucial to maintain a temperature of  $-75 \pm 5$  °C. The mixture was warmed to room temp. within 4 h and then was treated with HCl (2 M solution, 10 mL) to give a clear solution. TLC [petroleum ether/ethyl acetate, 4:1;  $R_{\rm f} = 0.41$  (3d),  $R_{\rm f} = 0.50$  (4d), and  $R_{\rm f} = 0.19$  (dimethyl malonate); KMnO<sub>4</sub>]. After evaporation of the solvent, the residue was dissolved in diethyl ether (200 mL), and the solution was washed with saturated NaHCO<sub>3</sub> solution ( $2 \times 50$  mL), water ( $2 \times 50$  mL), and brine (50 mL) and then dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (petroleum ether/diethyl ether, 10:1) to give 4d (1.88 g, 85%) as a colorless foam.  $[a]_{D}^{20} = -36.6 \ (c = 1.01, \text{ CHCl}_{3});$ 98% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.32$  [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 3.29-3.35 (m, 1 H, OCH<sub>a</sub>H<sub>b</sub>), 3.41 (dd, J = 8.4, 8.4 Hz, 1 H,  $OCH_aH_b$ , 3.60 (ddd, J = 17.2, 6.9, 1.4 Hz, 1 H, 2'-H<sub>a</sub>), 3.68 (ddd,  $J = 17.6, 6.6, 1.1 \text{ Hz}, 1 \text{ H}, 2'-\text{H}_{b}$ , 5.08–5.18 (m, 4 H, 3-H and 4'-H), 5.57-5.64 (m, 1 H, 1-H), 5.84 (ddd, J = 17.1, 10.7, 6.1 Hz, 1 H, 2-H), 5.96–6.10 (m, 1 H, 3'-H), 7.19–7.42 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 27.97 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 43.29 (t, C-2'), 56.21 (d, C-1), 64.14 (t, C-1''), 83.38 [s, C(CH<sub>3</sub>)<sub>3</sub>], 86.60 [s, C(Ph)<sub>3</sub>], 117.41 (t, C-3 or C-4'), 118.11 (t, C-3 or C-4'), 127.09 (3 d, C-Ar), 127.90 (6 d, C-Ar), 128.90 (6 d, C-Ar), 131.85 (d, C-3'), 135.25 (d, C-2), 144.05 (3 s, C-Ar), 153.15 [s, COOC(CH<sub>3</sub>)<sub>3</sub>], 174.25 (s, C-1') ppm. HRMS (ESI+): calcd. for  $C_{32}H_{36}NO_4^+$  [M + H]<sup>+</sup> 498.2639; found 498.2646.

**General Procedure for Ring-Closing Metathesis (GP3):** In a dry Schlenk flask under argon, a solution of diene **4** (1.0 equiv.) and Grubbs II catalyst [1.0-6.0 mol-%; for the preparation of **5d**, Grubbs I catalyst (5 mol-%)] in dry CH<sub>2</sub>Cl<sub>2</sub> (0.1–0.03 M) was heated at reflux until TLC indicated complete conversion. The mixture was concentrated in vacuo, and the residue was subjected to flash column chromatography on silica gel to yield lactam **5**.

(-)-(6S)-1-Benzyl-6-methyl-3,6-dihydropyridin-2(1H)-one (5a): GP3 was carried out using 4a (2.10 g, 9.16 mmol), Grubbs II catalyst (77.8 mg, 91.6  $\mu$ mol), and dry CH<sub>2</sub>Cl<sub>2</sub> (300 mL) for a reaction time of 5 h. TLC [petroleum ether/diethyl ether, 1:1;  $R_{\rm f} = 0.20$  (4a) and  $R_{\rm f} = 0.05$  (5a); KMnO<sub>4</sub>]. The mixture was concentrated in vacuo, and the residue was subjected to flash column chromatography on silica gel (petroleum ether/diethyl ether, 1:1) to yield 5a (1.65 mg, 93%) as a pale brown oil.  $[a]_D^{20} = -54.9$  (c = 1.19, CHCl<sub>3</sub>), 96.5% ee; ref.<sup>[29a]</sup>  $[a]_D^{20} = -34.5$  (c = 0.23, CHCl<sub>3</sub>). HPLC analysis (Daicel Chiralpak OJ-H, *n*-hexane/isopropanol, 90:10, 0.5 mL/min):  $t_{\rm R}$  = 22.7 [(-)-(S)-5a] and  $t_{\rm R} = 27.1 \text{ min}$  [(+)-(R)-5a]. <sup>1</sup>H NMR  $(300 \text{ MHz}, \text{CDCl}_3)$ :  $\delta = 1.24 \text{ (d, } J = 6.6 \text{ Hz}, 3 \text{ H}, \text{CH}_3)$ , 3.03-3.07(m, 2 H, 3-H), 3.81–3.94 (m, 1 H, 6-H), 4.05 (d, J = 15.2 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 5.43 (d, J = 15.2 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 5.64–5.78 (m, 2 H, 4-H and 5-H), 7.20-7.35 (m, 5 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 20.51 (q, CH<sub>3</sub>), 32.18 (t, C-3), 46.53 (t, PhCH<sub>2</sub>), 52.84 (d, C-6), 121.39 (d, C-4 or C-5), 127.78 (d, Ar), 127.87 (d, C-4 or C-5), 128.63 (d, Ar), 137.61 (s, Ar), 167.94 (s, C-2) ppm. GC-MS:  $t_{\rm R} = 10.7 \text{ min. HRMS (EI+): calcd. for } C_{13}H_{15}NO^+ [M]^+ 201.1154;$ found 201.1157.

(+)-(6R)-1-(4-Methoxybenzyl)-6-phenyl-3,6-dihydropyridin-2(1H)one (5b): GP3 was carried out using 4b (4.38 g, 13.6 mmol), Grubbs II catalyst (290 mg, 2.5 mol-%), and dry CH<sub>2</sub>Cl<sub>2</sub> (450 mL) for a reaction time of 2 h. TLC [petroleum ether/ethyl acetate, 2:1;  $R_{\rm f} = 0.37$  (4b) and  $R_{\rm f} = 0.14$  (5b); KMnO<sub>4</sub>]. The mixture was concentrated in vacuo, and the residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, from 2:1 to 1:1) to give 5b (3.66 g, 91%) as colorless plates; m.p. 68 -70 °C, which were suitable for X-ray crystal structure analysis.  $[a]_{D}^{20} = +98$  (c = 0.88, CHCl<sub>3</sub>); 98%ee). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 3.08 (m, 1 H, 3-H<sub>a</sub>), 3.13–3.24 (m, 1 H, 3-H<sub>b</sub>), 3.26  $(d, J = 14.8 \text{ Hz}, 1 \text{ H}, 1' \text{-H}_{a}), 3.72 (s, 3 \text{ H}, \text{OCH}_{3}), 4.73 (m, 1 \text{ H}, 6 \text{-}$ H), 5.48 (d, J = 14.7 Hz, 1 H, 1'-H<sub>b</sub>), 5.55–5.70 (m, 2 H, 4-H, 5-H), 6.77 (d, J = 8.7 Hz, 2 H, 3''-H), 7.02–7.13 (m, 4 H, Ar), 7.20– 7.34 (m, 3 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 32.25 (t, C-3), 45.74 (d, C-1'), 55.36 (q, OCH<sub>3</sub>), 61.47 (d, C-6), 114.07 (d, C-3''), 120.52 (d, C-4 or C-5), 126.50 (d, C-4 or C-5), 127.13 (d, C-Ar), 128.25 (d, C-Ar), 128.90 (s, C-1''), 129.19 (d, C-Ar), 129.79 (d, C-Ar), 140.24 (s, C-Ph), 159.08 (s, C-4''), 167.57 (s, C-2) ppm. GC-MS:  $t_{\rm R} = 17.80$  min. HRMS (ESI+): calcd. for C<sub>19</sub>H<sub>20</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 294.14929; found 294.14886.

(+)-(S)-1-Benzyl-6-[(trityloxy)methyl]-3,6-dihydropyridin-2(1H)-one (ent-5c): GP3 was carried out using ent-4c (4.24 g, 8.70 mmol), Grubbs II catalyst (440 mg, 0.52 mmol), and dry CH<sub>2</sub>Cl<sub>2</sub> (100 mL) for a reaction time of 19 h. TLC [petroleum ether/ethyl acetate, 5:1;  $R_{\rm f} = 0.25$  (ent-4c) and  $R_{\rm f} = 0.08$  (ent-5c); KMnO<sub>4</sub>]. The solvent was evaporated in vacuo, and the residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, 3:1) to yield ent-5c (4.03 g, quantitative) as a colorless oil.  $[a]_{D}^{20} = +12.7$  (c = 1.16, CHCl<sub>3</sub>); 94% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 2.98-3.19$  (m, 2 H, 3-H), 3.19–3.29 (m, 2 H, 1'-H), 3.72 (d, J = 15.3 Hz, 1 H, 1<sup>''</sup>-H<sub>a</sub>), 3.82-3.93 (m, 1 H, 6-H), 5.43 $(d, J = 15.3 \text{ Hz}, 1 \text{ H}, 1''-\text{H}_{b}), 5.67-5-79 \text{ (m, 1 H, 5-H)}, 5.91 \text{ (dt, } J$ = 10.0, 3.2 Hz, 1 H, 4-H), 7.02-7.11 (m, 2 H, Ar), 7.15-7.35 (m, 12 H, Ar), 7.35–7.44 (m, 6 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 32.98 (t, C-3), 47.02 (t, C-1''), 57.11 (d, C-6), 63.88 (t, C-1'), 87.22 [s, C(Ph)<sub>3</sub>], 124.33 (d, C-4), 124.61 (d, C-5), 127.31, 127.34, 127.85, 128.01, 128.66, 128.77 (6 d, Ar), 137.05 (s, NCH<sub>2</sub>Ph), 143.70 (s, Ar), 168.85 (s, C-2) ppm. HRMS (ESI+): calcd. for  $C_{32}H_{30}NO_2^+$  [M + H]<sup>+</sup> 460.2271; found 460.2272.

(+)-*tert*-Butyl (6*R*)-2-Oxo-6-[(trityloxy)methyl]-3,6-dihydropyridine-1(2*H*)-carboxylate (5d): GP3 was carried out using 4d (1.69 g,

3.39 mmol), Grubbs I catalyst (168 mg, 5 mol-%), and dry CH<sub>2</sub>Cl<sub>2</sub> (137 mL) for a reaction time of 16 h. TLC [petroleum ether/ethyl acetate, 4:1;  $R_{\rm f} = 0.51$  (4d) and  $R_{\rm f} = 0.24$  (5d); KMnO<sub>4</sub>]. The solvent was evaporated in vacuo, and the residue was subjected to flash column chromatography on silica gel (pentane/diethyl ether/ diethylamine, 3:1:0.02) to yield 5d (1.16 g, 73%) as a colorless foam.  $[a]_{D}^{20} = +103$  (c = 1.09, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 1.44$  [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 3.04–3.27 (m, 3 H, 3-H and  $OCH_aH_b$ ), 3.40 (dd, J = 9.2, 4.5 Hz, 1 H,  $OCH_aH_b$ ), 4.79 (m, 1 H, 6-H), 5.80–5.91 (m, 2 H, 4-H and 5-H), 7.19–7.38 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 28.10$  [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 35.67 (t, C-3), 57.08 (d, C-6), 64.78 (t, C-1'), 83.23 [s, C(CH<sub>3</sub>)<sub>3</sub>], 87.21 [s, C(Ph)<sub>3</sub>], 123.77 (d, C-4 or C-5), 124.79 (d, C-4 or C-5), 127.22 (3 d, C-Ar), 127.95 (6 d, C-Ar), 128.86 (6 d, C-Ar), 143.69 (3 s, C-Ar), 151.99 [s, COOC(CH<sub>3</sub>)<sub>3</sub>], 169.76 (s, C-2) ppm. HRMS (ESI+): calcd. for  $C_{30}H_{31}NNaO_4^+$  [M + Na]<sup>+</sup> 492.2145; found 492.2143.

General Procedure for Epoxidation/Elimination (GP4): Oxone (5.0 equiv.) was added in a few portions to a suspension of lactam 5 (1.0 equiv.) and NaHCO<sub>3</sub> (15.0 equiv.) in acetone/H<sub>2</sub>O (2:1, v/v; 2.1-9.2 mL per 100 mg of 5). The mixture was stirred at room temp. (for the preparation of 6a at 0 °C and afterwards at room temp.) until TLC indicated complete consumption of the starting material. The suspension was diluted with ethyl acetate, and the resulting solution was treated with aqueous  $Na_2S_2O_5$  (10% in H<sub>2</sub>O) as the mixture was vigorously stirred. The aqueous phase was separated and extracted with ethyl acetate. The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution and brine, dried with Na<sub>2</sub>SO<sub>4</sub>, and then concentrated in vacuo. A solution of the crude product and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 1.3-2.0 equiv.) in CH<sub>2</sub>Cl<sub>2</sub> (1.9-5.6 mL per 100 mg of 5) was stirred and heated at reflux (for the preparation of 6a at room temp. followed by stirring and heating at reflux) until TLC indicated complete conversion. The workup was initiated by the addition of a saturated aqueous NH<sub>4</sub>Cl solution or stirring for 1 h with Amberlite IR-120. The phases were separated, and the aqueous phase was extracted with ethyl acetate and washed with brine. The combined organic phases were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel. Regioselectivity was determined by <sup>1</sup>H NMR analysis of the crude product or isolation of the regioisomers.

(-)-(5R,6S)-1-Benzyl-5-hydroxy-6-methyl-5,6-dihydropyridin-2(1H)one (6a): GP4 was carried out using Oxone (15.03 g, 24.45 mmol), NaHCO<sub>3</sub> (6.16 g, 73.4 mmol), and **5a** (0.98 g, 4.89 mmol) in acetone/H<sub>2</sub>O (2:1, v/v, 90 mL) for a reaction time of 3 h at 0 °C and 1 h at room temp. TLC [ethyl acetate;  $R_f = 0.36$  (5a) and  $R_f = 0.21$ (epoxide); KMnO<sub>4</sub>]. After workup, the elimination reaction was carried out with the crude product, CH2Cl2 (50 mL), and DBU (1.49 g, 9.78 mmol), and the reaction mixture was stirred at room temp. for 11 h and then heated at reflux for 7 h. TLC [ethyl acetate;  $R_{\rm f} = 0.22$  (trans-6a) and  $R_{\rm f} = 0.30$  (cis-6a); KMnO<sub>4</sub>]. Column chromatography on silica gel (diethyl ether) afforded trans-6a (670 mg, 63%) as colorless needles and cis-6a (56 mg, 5%) as colorless needles. Data for (5R,6S)-trans-6a: M.p. 68-69 °C. NMR spectroscopic data are in accordance with reported data.<sup>[29a]</sup>  $[a]_{D}^{20} =$  $-156 (c = 0.49, \text{CHCl}_3), 96.5\% ee; \text{ref.}^{[29a]} [a]_{\text{D}}^{20} = -40.5 (c = 0.47, -10.5)$ CHCl<sub>3</sub>). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.13 (d, J = 6.9 Hz, 3 H, CH<sub>3</sub>), 1.75 (d, J = 8.9 Hz, 1 H, OH), 3.60 (qdd, J = 6.9, 1.6, 1.6 Hz, 1 H, 6-H), 3.90 (ddd, J = 8.9, 5.7, 1.6 Hz, 1 H, 5-H), 4.02  $(d, J = 14.8 \text{ Hz}, 1 \text{ H}, \text{PhCH}_{a}\text{H}_{b}), 5.26 (d, J = 14.8 \text{ Hz}, 1 \text{ H},$ PhCH<sub>a</sub>H<sub>b</sub>), 6.14 (d, J = 9.7 Hz, 1 H, 3-H), 6.59 (ddd, J = 9.7, 5.7,1.5 Hz, 1 H, 4-H), 7.22–7.39 (m, 5 H, Ar) ppm. <sup>13</sup>C NMR  $(75 \text{ MHz}, \text{CDCl}_3)$ :  $\delta = 17.02 \text{ (q, CH}_3)$ , 48.35 (t, PhCH<sub>2</sub>), 58.24 (d,

C-6), 66.48 (d, C-5), 127.60 (d, C-3), 128.29, 128.73 (2 d, Ar), 137.16 (s, Ar), 137.22 (d, C-4), 162.34 (s, C-2) ppm. GC–MS:  $t_{\rm R}$  = 11.5 min (*trans*-**6a**). HRMS (EI+): calcd. for C<sub>13</sub>H<sub>15</sub>NO<sub>2</sub><sup>+</sup> [M]<sup>+</sup> 217.1103; found 217.1087. Data for (*S*,*S*)-*cis*-**6a**: M.p. 122–124 °C. NMR spectroscopic data are in accordance with reported data.<sup>[29b]</sup> [a]<sub>D</sub><sup>20</sup> = +22.2 (c = 0.96, CHCl<sub>3</sub>), 96.5%*ee*; ref.<sup>[29b]</sup> [a]<sub>D</sub><sup>20</sup> = +21.8 (c = 0.45, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.17 (d, J = 6.7 Hz, 3 H, CH<sub>3</sub>), 3.42–3.54 (m, 1 H, 6-H), 3.84 (d, J = 15.1 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 4.62 (ddd, J = 6.3, 2.2, 2.2 Hz, 1 H, 5-H), 5.20 (d, J = 15.1 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 5.81 (dd, J = 10.0, 2.2 Hz, 1 H, 3-H), 6.34 (ddd, J = 10.0, 1.8, 1.8 Hz, 1 H, 4-H), 7.18–7.34 (m, 5 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 10.97 (q, CH<sub>3</sub>), 47.39 (t, PhCH<sub>2</sub>), 55.25 (d, C-6), 67.20 (d, C-5), 123.40 (d, C-3), 127.56, 127.82, 128.74 (3 d, Ar), 137.73 (s, Ar), 143.08 (d, C-4), 163.61 (s, C-2) ppm. GC–MS:  $t_{\rm R}$  = 11.8 min (*cis*-**6a**).

(-)-(5R,6S)-5-Hydroxy-1-(4-methoxybenzyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one (6b): GP4 was carried out using Oxone (31.45 g, 51.15 mmol), lactam **5b** (3.00 g, 10.22 mmol), and NaHCO<sub>3</sub> (12.87 g, 153.3 mmol) in acetone/H<sub>2</sub>O (2:1, v/v, 132 mL) for a reaction time of 7 h. TLC [petroleum ether/ethyl acetate, 1:2;  $R_{\rm f} = 0.22$ (5b) and  $R_{\rm f} = 0.30$  (epoxide); KMnO<sub>4</sub>] indicated incomplete conversion, and, therefore, Oxone (6.29 g, 10.30 mmol) and NaHCO<sub>3</sub> (2.57 g, 30.66 mmol) were added. After another 1 h, TLC indicated complete conversion. After workup, the elimination reaction was carried out with the crude product, DBU (2.02 g, 13.29 mmol), and CH<sub>2</sub>Cl<sub>2</sub> (167 mL), and the reaction mixture was heated at reflux for 3 h. TLC [petroleum ether/ethyl acetate, 1:2;  $R_{\rm f}$  (6b) = 0.22; KMnO<sub>4</sub>]. Chromatography on silica gel (petroleum ether/ethyl acetate/dichloromethane, 1:2:1) afforded 6b (1.922 g, 61%, trans-6b/cis-6b, 93:7) as a colorless foam. Separation of the diastereomers was accomplished by preparative HPLC (petroleum ether/ethyl acetate/dichloromethane, 5:5:4). Data for trans-6b: Colorless plates (1.640 g, 52%) that were suitable for X-ray crystal structure analysis; m.p. 108–109 °C.  $[a]_{D}^{20} = -13.8$ , (c = 0.99, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.05 (br. s, 1 H, OH), 3.55 (d, J = 14.7 Hz, 1 H, 1'-H<sub>a</sub>), 3.77 (s, 3 H, OCH<sub>3</sub>), 4.16 (dd, J = 5.8, 5.8 Hz, 1 H, 5-H), 4.66 (s, 1 H, 6-H), 5.47 (d, J = 14.7 Hz, 1 H, 1'-H<sub>b</sub>), 6.22 (d, J = 9.7 Hz, 1 H, 3-H), 6.47 (ddd, J = 9.7, 5.6, 1.0 Hz, 1 H, 4-H), 6.82 (d, J = 8.7 Hz, 2 H, 3<sup>''</sup>-H), 7.09–7.19 (m, 4 H, Ar), 7.25–7.38 (m, 3 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 47.49 (t, C-1'), 55.38 (q, OCH<sub>3</sub>), 65.90 (d, C-6), 68.07 (d, C-5), 114.20 (d, C-3"), 126.87 (d, Ar), 128.00, 128.22 (2 d, C-3, C-4""), 128.72 (s, C-1''), 129.04 (d, Ar), 129.82 (d, Ar), 136.59 (d, C-4), 136.79 (s, C-1'''), 159.10 (s, C-4''), 163.15 (s, C-2) ppm. HRMS (ESI+): calcd. for  $C_{19}H_{20}NO_3^+$  [M + H]<sup>+</sup> 310.14398; found 310.14404. Data for *cis*-**6b**: Colorless oil (100 mg, 3%).  $[a]_{\rm D}^{20} =$ +143, (c = 0.59, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$ = 1.70 (br. s, 1 H, OH), 3.37 (d, J = 14.7 Hz, 1 H, 1'-H<sub>a</sub>), 3.80 (s, 3 H, OCH<sub>3</sub>), 4.55 (dd, *J* = 7.7, 1.0 Hz, 1 H, 5-H), 4.86 (br. s, 1 H, 6-H), 5.45 (d, J = 14.7 Hz, 1 H, 1'-H<sub>b</sub>), 6.02 (dd, J = 10.0, 2.6 Hz, 1 H, 3-H), 6.22 (dd, *J* = 10.0, 1.7 Hz, 1 H, 4-H), 6.84 (d, *J* = 8.7 Hz, 2 H, 3''-H), 7.13 (d, J = 8.5 Hz, 2 H, 2''-H), 7.18–7.24 (m, 2 H, 2'''-H), 7.34–7.41 (m, 3 H, 3'''-H, 4'''-H) ppm. <sup>13</sup>C NMR  $(75 \text{ MHz}, \text{CDCl}_3): \delta = 47.12 \text{ (t, C-1')}, 55.42 \text{ (q, OCH}_3), 62.21 \text{ (d,})$ C-5), 67.31 (d, C-6), 114.20 (d, C-3"), 124.24 (d, C-3), 128.89 (d, C-3'''), 128.93 (d, C-4'''), 129.31 (s, C-1''), 129.34 (d, C-2'''), 129.74 (d, C-2"), 133.37 (s, C-1""), 142.24 (s, C-4), 159.25 (s, C-4"), 163.69 (s, C-2) ppm. HRMS (ESI+): calcd. for C<sub>19</sub>H<sub>20</sub>NO<sub>3</sub><sup>+</sup>  $[M + H]^+$  310.14377; found 310.14404.

(+)-(55,6R)-1-Benzyl-5-hydroxy-6-[(trityloxy)methyl]-5,6-dihydropyridin-2(1*H*)-one (*ent-trans*-6c): GP4 was carried out with Oxone (6.89 g, 11.20 mmol), lactam *ent*-5c (1.03 g, 2.24 mmol), NaHCO<sub>3</sub> (2.82 g, 33.6 mmol), and acetone/water (2:1, v/v, 25 mL) for a reac-



tion time of 2 h at room temp. TLC [petroleum ether/ethyl actetate, 2:1;  $R_{\rm f} = 0.26$  (*ent*-**5**c) and  $R_{\rm f} = 0.22$  (epoxide); KMnO<sub>4</sub>]. After workup, the elimination reaction was carried out with the crude product, CH<sub>2</sub>Cl<sub>2</sub> (40 mL), and DBU (0.61 g, 4.03 mmol) for a reaction time of 7 h. TLC [petroleum ether/ethyl actetate; 2:1;  $R_{\rm f} = 0.22$ (epoxide) and  $R_f = 0.15$  (*ent-trans-6c*); KMnO<sub>4</sub>]. Chromatography on silica gel (petroleum ether/ethyl acetate, from 2:1 to 1:1) afforded ent-trans-6c (906 mg, 85%, single diastereoisomer) as a colorless foam.  $[a]_{D}^{20} = +38.4 (c = 1.07, CHCl_3); 94\% ee.$  <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 2.09$  (d, J = 8.5 Hz, 1 H, OH), 2.90 (dd, J = 9.6, 8.8 Hz, 1 H, 1'-H<sub>a</sub>), 3.16 (dd, J = 9.8, 4.9 Hz, 1 H, 1'-H<sub>b</sub>), 3.50-3.62 (m, 1 H, 6-H), 3.80 (d, J = 14.8 Hz, 1 H, 1''-H), 4.23 (dd, J= 6.2, 6.2 Hz, 1 H, 5-H), 5.02 (d, J = 14.8 Hz, 1 H, 1"-H), 5.91 (d, J = 9.8 Hz, 1 H, 3-H), 6.37 (ddd, J = 9.7, 5.7, 1.3 Hz, 1 H, 4-H), 7.06–7.31 (m, 20 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ = 48.68 (t, C-1''), 62.11 (t, C-1'), 62.21 (d, C-6), 62.83 (d, C-5), 87.57 [s, C(Ph)<sub>3</sub>], 127.25 (d, C-3), 127.40, 127.71, 128.06, 128.34, 128.65, 128.79 (6 d, Ar), 136.99 (d, C-4), 137.11 (s, NCH<sub>2</sub>Ph), 143.52 (s, Ar), 162.47 (s, C-2) ppm. HRMS (ESI+): calcd. for  $C_{32}H_{30}NO_3^+$  [M + H]<sup>+</sup> 476.2220; found 476.2221.

(-)-tert-Butyl (2S,3R)-3-Hydroxy-6-oxo-2-[(trityloxy)methyl]-3,6-dihydropyridine-1(2H)-carboxylate (6d): GP4 was carried out with Oxone (3.70 g, 6.02 mmol), lactam 5d (565 mg, 1.20 mmol), NaHCO<sub>3</sub> (1.52 g, 18.06 mmol), and acetone/water (2:1, v/v, 12 mL) for a reaction time of 4 h at room temp. TLC [petroleum ether/ ethyl acetate, 3:1;  $R_{\rm f} = 0.33$  (5d) and  $R_{\rm f} = 0.23$  (epoxide); KMnO<sub>4</sub>]. After workup, a yellowish foam (531 mg) was obtained. The elimination reaction was carried out by the addition of CH<sub>2</sub>Cl<sub>2</sub> (11 mL) and DBU (0.33 g, 2.20 mmol) for a reaction time of 2 h. TLC [petroleum ether/ethyl actetate, 2:1;  $R_{\rm f} = 0.36$  (epoxide) and  $R_{\rm f} = 0.18$ (6d); KMnO<sub>4</sub>]. Chromatography on silica gel (diethyl ether/diethylamine, 1:0.005) afforded 6d (527 mg, 90%, single diastereomer) as a colorless foam.  $[a]_{D}^{20} = -30.3$  (c = 1.32, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (500 MHz,  $CD_2Cl_2$ ):  $\delta = 1.46$  [s, 9 H,  $C(CH_3)_3$ ], 2.51 (br. s, 1 H, OH), 3.04 (dd, J = 9.2, 8.2 Hz, 1 H, OCH<sub>a</sub>H<sub>b</sub>), 3.31 (dd, J =9.2, 4.8 Hz, 1 H, OCH<sub>a</sub>H<sub>b</sub>), 4.40 (dd, J = 5.9, 1.2 Hz, 1 H, 3-H), 4.64–4.68 (m, 1 H, 2-H), 5.90 (d, J = 9.6 Hz, 1 H, 5-H), 6.61 (ddd, J = 9.7, 5.8, 1.5 Hz, 1 H, 4-H), 7.24–7.39 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (125 MHz,  $CD_2Cl_2$ ):  $\delta$  = 28.27 [3 q,  $C(CH_3)_3$ ], 61.51 (d, C-3), 63.27 (d, C-2), 63.74 (t, C-1'), 83.71 [s, C(CH<sub>3</sub>)<sub>3</sub>], 87.73 [s, C(Ph)<sub>3</sub>], 127.74 (3 d, C-Ar), 128.14 (d, C-5), 128.47 (6 d, C-Ar), 129.08 (6 d, C-Ar), 139.59 (d, C-4), 144.08 (3 s, C-Ar), 152.40 [s, COOC(CH<sub>3</sub>)<sub>3</sub>], 162.45 (s, C-6) ppm. HRMS (ESI+): calcd. for C<sub>30</sub>H<sub>31</sub>NNaO<sub>5</sub><sup>+</sup> [M + Na]<sup>+</sup> 508.2094; found 508.2102.

(+)-(5S,6R)-1-Benzyl-5-(benzyloxy)-6-[(trityloxy)methyl]-5,6-dihydropyridin-2(1H)-one (7): Under argon, a solution of ent-trans-6c (1.00 g, 2.10 mmol) in dry THF (20 mL) was cooled to 0 °C. NaH (126 mg, 5.26 mmol) was added, and the mixture was stirred for 20 min and then warmed to room temp. Tetrabutylammonium iodide (155 mg, 0.42 mmol) and BnBr (1.26 g, 7.36 mmol) were added, and the mixture was gently heated at reflux. After 7 h, TLC [petroleum ether/ethyl acetate, 2:1;  $R_f = 0.09$  (*ent-trans-6c*) and  $R_f = 0.31$ (7); KMnO<sub>4</sub>] indicated complete consumption of the starting material. The mixture was concentrated in vacuo, and the residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, 3:1) to give benzyl ether 7 (1.16 g, 97%) as light yellow foam.  $[a]_{D}^{20} = +58.1$  (c = 1.13, CHCl<sub>3</sub>); 94% ee. <sup>1</sup>H NMR  $(500 \text{ MHz}, \text{CDCl}_3): \delta = 3.01 \text{ (dd}, J = 9.4, 9.4 \text{ Hz}, 1 \text{ H}, 1'-\text{H}_a), 3.30$  $(dd, J = 9.9, 4.7 Hz, 1 H, 1'-H_b), 3.70 (dd, J = 8.8, 4.7 Hz, 1 H, 6-$ H), 3.75 (d, J = 15.2 Hz, 1 H, 1<sup>''</sup>-H<sub>a</sub>), 4.11 (d, J = 5.6 Hz, 1 H, 5-H), 4.29 (d, J = 11.8 Hz, 1 H, 1<sup>'''</sup>-H<sub>a</sub>), 4.35 (d, J = 11.8 Hz, 1 H,  $1'''-H_{\rm b}$ ), 5.29 (d, J = 15.1 Hz, 1 H,  $1''-H_{\rm b}$ ), 6.07 (d, J = 9.8 Hz, 1 H, 3-H), 6.37 (ddd, J = 9.6, 5.7, 0.9 Hz, 1 H, 4-H), 7.11–7.19 (m,

2 H, Ar), 7.20–7.39 (m, 23 H, Ar) ppm. <sup>13</sup>C NMR (125 Hz, CDCl<sub>3</sub>):  $\delta$  = 48.04 (t, C-1''), 58.05 (d, C-6), 61.88 (t, C-1'), 68.69 (d, C-5), 70.24 (t, C-1'''), 87.63 [s, C(Ph)<sub>3</sub>], 127.41 (d, C-3), 127.45, 127.84, 127.91, 128.07, 128.18, 128.52, 128.63 (7 d, Ar), 134.56 (d, C-4), 137.06 (s, NCH<sub>2</sub>Ph), 137.77 (s, OCH<sub>2</sub>Ph), 143.56 (s, Ar), 162.46 (s, C-2) ppm. HRMS (ESI+): calcd. for C<sub>39</sub>H<sub>36</sub>NO<sub>3</sub><sup>+</sup> [M + H]<sup>+</sup> 566.2689; found 566.2688.

(+)-(3S,4R,5R,6R)-1-Benzyl-5-(benzyloxy)-3,4-dihydroxy-6-[(trityloxy)methyl]piperidin-2-one (8): A drop of water, four drops of pyridine, and osmium tetroxide (2.5% OsO<sub>4</sub> in *tert*-butanol, 1.8 mL) were added to a stirred solution of the dihydropyridinone 7 (540 mg, 0.955 mmol) and NMO (336 mg, 2.87 mmol) in tert-butanol (3 mL). The reaction mixture was stirred for 3.5 h at room temp., and aqueous saturated  $Na_2S_2O_5$  (8 mL) and water (20 mL) were then added. The mixture was extracted with EtOAc (50 mL). TLC [ethyl acetate;  $R_f = 0.67$  (7) and  $R_f = 0.58$  (8); KMnO<sub>4</sub>]. The organic phase was washed with a saturated NH<sub>4</sub>Cl solution (20 mL) and then  $H_2O$  (2 × 20 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The crude product was purified by flash column chromatography on silica gel (petroleum ether/ethyl acetate, 3:1) to yield diol 8 (424 mg, 74%, single diastereomer) as a colorless foam.  $[a]_{D}^{20} = +2.5$  (c = 1.20, CHCl<sub>3</sub>); 94% ee. <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ ):  $\delta = 2.67$  (br. s, 1 H, OH), 3.38 (dd, J = 9.7, 4.7 Hz, 1 H,  $1'-H_a$ ), 3.60 (dd, J = 16.8, 7.0 Hz, 1 H,  $1'-H_b$ ), 3.58–3.69 (m, 1 H, 6-H), 3.84 (br. s, 1 H, OH), 4.01 (dd, J = 3.4, 2.7 Hz, 1 H, 5-H), 4.09 (d, J = 15.5 Hz, 1 H, 1"-H<sub>a</sub>), 4.33 (dd, J = 3.6, 3.6 Hz, 1 H, 4-H), 4.41 (d, J = 3.7 Hz, 1 H, 3-H), 4.43 (d, J = 11.9 Hz, 1 H,  $1'''-H_a$ ) 4.47 (d, J = 11.9 Hz, 1 H,  $1'''-H_b$ ), 5.11 (d, J = 15.5 Hz, 1 H, 1''-H<sub>b</sub>), 6.94–7.05 (m, 2 H, Ar), 7.11–7.49 (m, 23 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 47.68 (t, C-1''), 59.91 (d, C-6), 63.44 (t, C-1'), 68.12 (d, C-3), 68.94 (d, C-4), 71.62 (t, C-1'''), 74.60 (d, C-5), 87.64 [s, C(Ph)<sub>3</sub>], 127.32, 127.46, 127.75, 128.03, 128.59, 128.63, 128.74 (7 d, Ar), 136.76 (s, NCH<sub>2</sub>Ph), 137.46 (s, OCH<sub>2</sub>Ph), 143.73 (s, Ar), 171.25 (s, C-2) ppm. HRMS (ESI+): calcd. for  $C_{39}H_{37}NNaO_5^+$  [M + Na]<sup>+</sup> 622.2564; found 622.2566.

(+)-(3R,4R,5R,6R)-1-Benzyl-5-(benzyloxy)-6-[(trityloxy)methyl]piperidine-3,4-diol (9): Under argon, a solution of 8 (230 mg, 0.384 mmol) in dry Et<sub>2</sub>O (20 mL) was treated with LiAlH<sub>4</sub> (73.0 mg, 1.92 mmol). After 5 h [ $R_f$  of 8 and  $R_f$  of 9 were identical], the suspension was cooled to 0 °C and treated with 10% aqueous NaOH. The mixture was treated with EtOAc (40 mL), and the resulting mixture was filtered through a pad of Celite. Water (40 mL) was added, and the organic layer was separated. The aqueous layer was extracted with EtOAc ( $3 \times 30$  mL). The organic phase was dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, 3:1) to yield 9 (193 mg, 86%) as a colorless foam.  $[a]_{D}^{20} = +4.8 \ (c = 0.95, \text{CHCl}_3); 94\% ee. {}^{1}\text{H NMR} \ (300 \text{ MHz},$ CDCl<sub>3</sub>):  $\delta$  = 2.17 (dd, J = 12.3, 1.0 Hz, 1 H, 2-H<sub>a</sub>), 2.52 (br. s, 2 H, 2 OH), 2.57 (ddd, J = 8.4, 4.2, 1.3 Hz, 1 H, 6-H), 2.89 (dd, J = 12.3, 4.2 Hz, 1 H, 2-H<sub>b</sub>), 3.09 (d, J = 13.3 Hz, 1 H, 1<sup>''</sup>-H<sub>a</sub>), 3.27 (dd, J = 10.2, 4.5 Hz, 1 H, 1'-H<sub>a</sub>), 3.57 (dd, J = 16.7, 8.2 Hz, 1 H, 5-H), 3.57–3.78 (m, 3 H, 4-H, 1'-H<sub>b</sub> and 3-H), 4.11 (d, *J* = 13.0 Hz, 1 H, 1''-H<sub>b</sub>), 4.47 (d, J = 11.3 Hz, 1 H, 1'''-H<sub>a</sub>), 4.87 (d, J =11.2 Hz, 1 H, 1'''-H\_b), 7.01–7.09 (m, 4 H, Ar), 7.09–7.32 (m, 15 H, Ar), 7.36–7.50 (m, 6 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 54.58 (t, C-2), 57.35 (t, C-1''), 62.16 (t, C-1'), 65.65 (d, C-6), 68.20 (d, C-3), 74.19 (t, C-1'''), 76.45 (d, C-4), 78.54 (d, C-5), 86.93 [s, C(Ph)<sub>3</sub>], 127.19, 127.62, 127.95, 128.13, 128.42, 128.50, 128.91, 129.06 (8 d, Ar), 138.46 (s, NCH<sub>2</sub>Ph), 138.75 (s, OCH<sub>2</sub>Ph), 143.89 (s, Ar) ppm. HRMS (ESI+): calcd. for  $C_{39}H_{40}NO_4^+$  [M + H]<sup>+</sup> 586.2951; found 586.2951.

(+)-(3R,4R,5R,6R)-1-Benzyl-5-(benzyloxy)-6-(hydroxymethyl)piperidine-3,4-diol (10): AcOH (80% in H<sub>2</sub>O, 5 mL) was added to the protected piperidinediol 9 (75 mg, 0.128 mmol), and the resulting yellow mixture was stirred and heated at reflux for 6 h whereupon TLC [ethyl acetate;  $R_f = 0.63$  (9) and  $R_f = 0.19$  (10); KMnO<sub>4</sub>] indicated full conversion. The mixture was diluted with H<sub>2</sub>O (10 mL), and the resulting mixture was treated with solid NaHCO<sub>3</sub> until it became basic. Ethyl acetate (20 mL) was added to the resulting suspension, and the organic layer was separated. The aqueous layer was extracted with EtOAc ( $3 \times 20$  mL), and the organic layer was concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (ethyl acetate) to yield 10 (34.7 mg, 79%) as a colorless foam. Analytical data were in accordance with data from the literature.<sup>[11c]</sup> <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 2.14–2.30 (m, 2 H, 2-H<sub>a</sub> and 6-H), 2.53 (br. s, 3 H, 3 OH), 2.93 (dd, J = 12.6 Hz, J = 4.1 Hz, 1 H, 2-H<sub>b</sub>), 3.31 (d, J =13.5 Hz, 1 H, 1''-H<sub>a</sub>), 3.52 (dd, J = 8.7 Hz, J = 3.4 Hz, 1 H, 4-H), 3.71 (dd, J = 8.7 Hz, J = 8.7 Hz, 1 H, 5-H), 3.75-3.80 (m, 1 H, 3-H), 3.85 (dd, J = 12.2 Hz, J = 2.1 Hz, 1 H, 1'-H<sub>a</sub>), 3.95 (dd, J =12.1 Hz, J = 2.8 Hz, 1 H, 1'-H<sub>b</sub>), 4.05 (d, J = 13.5 Hz, 1 H, 1''- $H_{\rm b}$ ), 4.68 (d, J = 11.2 Hz, 1 H, 1<sup>''</sup>- $H_{\rm a}$ ), 4.84 (d, J = 11.2 Hz, 1 H, 1<sup>'''</sup>-H<sub>b</sub>), 7.13–7.35 (m, 10 H, Ar) ppm.

1-Deoxymannojirimycin Hydrochloride (11·HCl): Pd(OH)<sub>2</sub>/C (20% Pd, 100 mg) was added to a stirred solution of piperidine 10 (40 mg, 0.116 mmol) in MeOH (1.5 mL), and the mixture was placed under a hydrogen atmosphere (1 bar). TLC [ethyl acetate;  $R_{\rm f} = 0.19$  (10)] indicated full conversion after 3 h. Then, concentrated HCl (1 mL) was added, and the mixture was stirred for an additional 10 min and diluted with MeOH (10 mL). The resulting mixture was filtered through a pad of Celite. The filtrate was concentrated in vacuo, and the residue recrystallized from MeOH to give 1-deoxymannojirimycin hydrochloride (11·HCl, 16.0 mg, 69%) as colorless needles. Analytical data were in accordance with data from the literature.<sup>[11c]</sup> M.p. 190-192 °C; ref.<sup>[11c]</sup> m.p. 192-195 °C. <sup>1</sup>H NMR (600 MHz, D<sub>2</sub>O):  $\delta$  = 3.11–3.28 (m, 1 H, 5-H), 3.30 (d,  $J = 13.8 \text{ Hz}, 1 \text{ H}, 6 \text{-H}_{a}$ , 3.47 (dd,  $J = 13.7, 1.9 \text{ Hz}, 1 \text{ H}, 6 \text{-H}_{b}$ ), 3.75 (dd, J = 9.6, 2.0 Hz, 1 H, 3 -H), 3.82 -- 3.98 (m, 2 H, 1-Ha, 4-H), 4.03 (dd, J = 12.5, 2.28 Hz, 1 H, 1-H<sub>b</sub>), 4.24–4.36 (m, 1 H, 2-H) ppm. <sup>13</sup>C NMR (150 MHz, D<sub>2</sub>O):  $\delta$  = 47.59 (t, C-6), 58.11 (t, C-1'), 60.27 (d, C-2), 65.73, 65.94 (2 d, C-3 and C-4), 72.31 (d, C-5) ppm.

(+)-(6S)-1-Benzyl-6-methylpiperidine-2,5-dione (13a): A suspension of Pd/C (10% Pd, 30 wt.-%, 60 mg) and *trans*-6a (200 mg, 0.92 mmol) in ethyl acetate (9 mL) was vigorously stirred under a hydrogen atmosphere (1 atm). TLC [ethyl acetate;  $R_{\rm f} = 0.22$  (trans-**6a**),  $R_{\rm f} = 0.30$  (*cis***-6a**), and  $R_{\rm f} = 0.10$  (*trans***-12a**); KMnO<sub>4</sub>] showed that the reaction was complete after 1 h. The suspension was filtered through a pad of Celite, and the solvent was removed in vacuo. The crude hydrogenation product was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (9 mL), and Dess-Martin periodinane (585 mg, 1.379 mmol) was added at 0 °C. After stirring for 1 h, TLC showed complete conversion [ethyl acetate;  $R_f = 0.36$  (13a); KMnO<sub>4</sub>]. Saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (4 mL) and saturated NaHCO<sub>3</sub> solution (8 mL) were added at 0 °C. After stirring for 10 min, the organic layer was separated, and the aqueous layer was extracted with diethyl ether  $(3 \times 15 \text{ mL})$ . The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo at a temperature not exceeding 10 °C. The residue was subjected to flash chromatography on silica gel (diethyl ether) to yield 13a (198 mg, 99%) as colorless needles; m.p. 63-64 °C. NMR spectroscopic data were in accordance with reported data for the racemic compound.<sup>[11c]</sup>  $[a]_D^{20} = +104$  (c = 0.93, CHCl<sub>3</sub>). HPLC (Daicel Chiralpak AD-H, n-hexane/isopropanol, 90:10, 0.5 mL/min):  $t_{\rm R} = 28.6 [(-)-(R)-13a]$  and  $t_{\rm R} = 45.2 \min [(+)-13a]$ 

(*S*)-13a]; 96.5% *ee.* <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.36 (d, *J* = 7.2 Hz, 3 H, CH<sub>3</sub>), 2.63–2.87 (m, 4 H, 3-H and 4-H), 3.74 (q, *J* = 7.2 Hz, 1 H, 6-H), 4.04 (d, *J* = 14.9 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 5.25 (d, *J* = 14.9 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 7.20–7.37 (m, 5 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 17.58 (q, CH<sub>3</sub>), 29.28, 35.51 (2 t, C-3 and C-4), 47.52 (t, PhCH<sub>2</sub>), 60.73 (d, C-6), 127.95, 128.16, 128.97 (3 d, Ar), 136.52 (s, Ar), 169.55 (s, C-2), 207.10 (s, C-5) ppm. GC–MS:  $t_{\rm R}$  = 11.1 min. HRMS (ESI+): calcd. for C<sub>13</sub>H<sub>16</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 218.1176; found 218.1176.

(-)-(5S,6S)-1-Benzyl-5-hydroxy-6-methylpiperidin-2-one (cis-12a): NaBH<sub>4</sub> (121 mg, 3.22 mmol) was added to a solution of 13a (70.2 mg, 0.32 mmol) in methanol (9 mL) at 0 °C. The resulting mixture was stirred for 30 min at 0 °C and 45 min at room temperature whereupon TLC showed complete conversion [ethyl acetate;  $R_{\rm f} = 0.36$  (13a) and  $R_{\rm f} = 0.12$  (*cis*-12a); KMnO<sub>4</sub>]. The reaction mixture was treated with a saturated NH<sub>4</sub>Cl solution (1 mL), and the resulting mixture was concentrated in vacuo. The residue was diluted with water (3 mL), and the solution was extracted with  $CH_2Cl_2$  (4 × 5 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (ethyl acetate) to yield *cis*-12a (67 mg, 95%, 92:8 mixture of diastereoisomers as determined by GC-MS) as a colorless amorphous solid. Pure cis-12a (57 mg, 81%) was obtained as colorless plates by preparative HPLC (petroleum ether/2-propanol, 70:30); m.p. 118-119 °C. NMR spectroscopic data were in accordance with published data for the racemic compound.<sup>[19]</sup>  $[a]_{D}^{20} = -114$  (c = 1.11, CHCl<sub>3</sub>). HPLC (Daicel Chiralpak AD-H, n-hexane/isopropanol, 90:10, 0.5 mL/min):  $t_{\rm R} = 30.2 [(+)-(R,R)-12a]$  and  $t_{\rm R} = 31.9 \min [(-)-(S,S)-12a]$ **12a**]; 96% *ee.* <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.19 (d, J = 6.6 Hz, 3 H, CH<sub>3</sub>), 1.80–1.88 (m, 1 H, 4-H<sub>a</sub>), 1.90–2.00 (m, 1 H, 4-H<sub>b</sub>),  $2.40-2.50 \text{ (m, 1 H, 3-H_a)}, 2.57 \text{ (ddd, } J = 18.3, 7.4, 3.8 \text{ Hz}, 1 \text{ H, 3-}$ H<sub>b</sub>), 2.89 (br. s, 1 H, OH), 3.38–3.44 (m, 1 H, 6-H), 3.88–3.96 (m, 1 H, 5-H), 3.91 (d, J = 15.0 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 5.26 (d, J =15.0 Hz, 1 H, PhCH<sub>a</sub>H<sub>b</sub>), 7.19 (d, J = 7.1 Hz, 2 H, Ar), 7.21–7.32 (m, 3 H, Ar) ppm. <sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>):  $\delta$  = 13.32 (q, CH<sub>3</sub>), 24.90 (t, C-4), 29.12 (t, C-3), 47.83 (t, PhCH<sub>2</sub>), 55.09 (d, C-6), 67.37 (d, C-5), 127.46, 127.86, 128.70 (3 d, Ar), 137.43 (s, Ar), 169.52 (s, C-2) ppm. GC–MS:  $t_{\rm R}$  = 12.2 min. HRMS (EI+): calcd. for C<sub>13</sub>H<sub>17</sub>NO<sub>2</sub><sup>+</sup> [M]<sup>+</sup> 219.1259; found 219.1249.

(-)-(5R,6S)-5-Hydroxy-1-(4-methoxybenzyl)-6-phenylpiperidin-2one (trans-12b): A suspension of Rh/C (10%, 69 mg) and trans-6b (690 mg, 2.23 mmol) in ethyl acetate (16 mL) and methanol (3 mL) was vigorously stirred for 5 h under hydrogen (1 atm). The suspension was filtered through a pad of Celite, and the solvent was removed in vacuo to yield 12b (688 mg, 98%) as a colorless solid; m.p. 132–134 °C.  $[a]_D^{20} = -48.5$  (c = 0.83, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR  $(300 \text{ MHz}, \text{CDCl}_3): \delta = 1.65 - 1.80 \text{ (m, 1 H, 4-Ha)}, 1.81 - 1.98 \text{ (m, 1 Ha)}$ H, 4-H<sub>b</sub>), 2.40–2.60 (m, 1 H, 3-H<sub>a</sub>), 2.77 (ddd, J = 17.9, 10.7,7.0 Hz, 1 H, 3-H<sub>b</sub>), 3.31 (d, J = 14.8 Hz, 1'-H<sub>a</sub>), 3.76 (s, 3 H,  $OCH_3$ ), 3.95–4.03 (m, 1 H, 5-H), 4.38 (d, J = 3.0 Hz, 1 H, 6-H), 5.55 (d, J = 14.8 Hz, 1 H, 1'-H<sub>b</sub>), 6.80 (d, J = 8.6 Hz, 2 H, 3''-H), 7.08 (d, J = 8.6 Hz, 2 H, 2''-H), 7.16 (dd, J = 7.16, 1.4 Hz, 2 H, 2''-H), 7.28–7.42 (m, 3 H, 3'''-H, 4'''-H) ppm. <sup>13</sup>C NMR (75 MHz,  $CDCl_3$ ):  $\delta = 23.38$  (t, C-4), 27.41 (t, C-3), 47.12 (t, C-1'), 55.36 (q, OCH<sub>3</sub>), 66.83 (d, C-6), 69.99 (d, C-5), 114.07 (d, C-3''), 127.01 (d, C-2'''), 128.16 (d, C-4'''), 128.95 (s, C-1''), 129.13 (d, C-3'''), 129.54 (d, C-2"), 138.75 (s, C-1""), 158.98 (s, C-4"), 170.30 (s, C-2) ppm. GC–MS ( $T_{\text{max}}$  = 300 °C):  $t_{\text{R}}$  = 16.21 min. HRMS (ESI+): calcd. for  $C_{19}H_{22}NO_3^+$  [M + H]<sup>+</sup> 312.15975; found 312.15942.

(+)-(6S)-1-(4-Methoxybenzyl)-6-phenylpiperidine-2,5-dione (13b): DMSO (146  $\mu$ L, 2.056 mmol) was added to a solution of oxalyl



chloride (90 µL, 1.028 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.3 mL) at -78 °C. After stirring for 10 min at the same temperature, a solution of *trans*-12b (80 mg, 257 µmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.3 mL) was added dropwise, and the suspension was stirred for an additional 20 min. NEt<sub>3</sub> (570  $\mu$ L, 4.112 mmol) was then added dropwise, and the stirring was continued at -78 °C for 30 min whereupon TLC indicated complete conversion [petroleum ether/ethyl acetate, 1:2;  $R_{\rm f} = 0.45$  (trans-12b) and  $R_{\rm f} = 0.18$  (13b); KMnO<sub>4</sub>]. The solution was treated with a NaH<sub>2</sub>PO<sub>4</sub>/Na<sub>2</sub>HPO<sub>4</sub> buffer solution (5 mL), and the resulting solution was warmed to ambient temperature and extracted with  $CH_2Cl_2$  (3 × 5 mL). The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (petroleum ether/ethyl acetate/dichloromethane, 2:1:0.2) to yield 13b (68.2 mg, 86%) as a colorless white solid; m.p. 119–121 °C.  $[a]_{D}^{20} = +20.1$  (c = 0.69, CHCl<sub>3</sub>). HPLC (Daicel Chiracel ADH-II, *n*-hexane/*i*PrOH, 80:20, 0.5 mL/min):  $t_{\rm R} = 23.53$  [(-)-(R)-13b] and  $t_{\rm R} = 26.93$  min [(+)-(S)-13b]; 98% ee. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = 2.64-2.74$ (m, 2 H, 3-H or 4-H), 2.74–2.86 (m, 2 H, 3-H or 4-H), 3.46 (d, J  $= 14.5 \text{ Hz}, 1 \text{ H}, 1' \text{-H}_{a}$ , 3.77 (s, 3 H, OCH<sub>3</sub>), 4.74 (s, 1 H, 6-H), 5.54 (d, J = 14.5 Hz, 1 H, 1'-H<sub>b</sub>), 6.81 (d, J = 8.7 Hz, 2 H, 3''-H), 7.07 (d, J = 8.5 Hz, 2 H, 2''-H), 7.21–7.27 (m, 2 H, 2'''-H), 7.20– 7.43 (m, 3 H, 3'''-H, 4'''-H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$ = 29.40 (t, C-4), 35.09 (t, C-3), 47.28 (t, C-1'), 55.43 (q, OCH<sub>3</sub>), 68.41 (d, C-6), 114.37 (d, C-3"), 126.66 (d, C-2""), 127.99 (s, C-1''), 128.78 (d, C-4'''), 129.44 (d, C-3'''), 129.97 (d, C-2''), 134.22 (s, C-1'''), 159.47 (s, C-4''), 170.00 (s, C-2), 202.97 (s, C-5) ppm. HRMS (ESI+): calcd. for  $C_{19}H_{20}NO_3^+$  [M + H]<sup>+</sup> 310.14413; found 310.14377.

(-)-(5S,6S)-5-Hydroxy-1-(4-methoxybenzyl)-6-phenyl-5,6-dihydropyridin-2(1H)-one (cis-12b): NaBH<sub>4</sub> (75.6 mg, 2 mmol) was added to a solution of 13b (62 mg, 0.2 mmol) in methanol (4 mL) at 0 °C. The resulting mixture was stirred for 30 min at 0 °C and 30 min at room temp. whereupon TLC [petroleum ether/ethyl acetate, 1:2;  $R_{\rm f}$ = 0.19 (*cis*-12b); KMnO<sub>4</sub>] indicated complete consumption of the starting material. Aqueous NH<sub>4</sub>Cl solution (3 mL) was added, and the mixture was concentrated under reduced pressure. Water (2.5 mL) was added, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>  $(3 \times 5 \text{ mL})$ . The combined organic layers were dried with Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated in vacuo to give cis-12 (66.4 mg, 97%) as a colorless solid, m.p. 171-173 °C; ref.<sup>[20]</sup> m.p. 172.5-173.5 °C. Analytical data are in accordance with reported data.<sup>[20]</sup>  $[a]_{\rm D}^{20} =$ -64.2 (c = 0.6, CHCl<sub>3</sub>); 98% ee; ref.<sup>[20]</sup> [a]<sub>D</sub><sup>20</sup> = -63.39 (c = 0.6, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = 1.45 (br. s, 1 H, OH), 1.68–1.78 (m, 2 H, 4-H), 2.59 (ddd, J = 18.1, 8.6, 8.6 Hz, 1 H, 3- $H_a$ ), 2.77 (ddd, J = 18.3, 5.2, 5.2 Hz, 1 H, 3- $H_b$ ), 3.29 (d, J =14.5 Hz, 1 H, 1'-H<sub>a</sub>), 3.79 (s, 3 H, OCH<sub>3</sub>), 4.03 (br. s, 1 H, 5-H), 4.48 (d, J = 5.3 Hz, 1 H, 6-H), 5.42 (d, J = 14.5 Hz, 1 H, 1'-H<sub>b</sub>), 6.84 (d, J = 8.7 Hz, 2 H, 3''-H), 7.06 (d, J = 8.6 Hz, 2 H, 2''-H), 7.22 (dd, J = 7.6, 1.7 Hz, 2 H, 2'''-H), 7.35–7.48 (m, 3 H, 3'''-H, 4'''-H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = 25.62 (t, C-4), 29.63 (t, C-3), 47.46 (t, C-1'), 55.41 (q, OCH<sub>3</sub>), 63.47 (d, C-6), 67.37 (d, C-5), 114.13 (d, C-3''), 128.68 (d, C-4'''), 128.74 (d, C-2'''), 128.93 (d, C-3'''), 129.02 (s, C-1''), 129.85 (d, C-2''), 135.45 (s, C-1'''), 159.19 (s, C-4''), 169.84 (s, C-2) ppm. GC–MS:  $t_{\rm R} = 20.08$  min. HRMS (ESI+): calcd. for  $C_{19}H_{22}NO_3^+$  [M + H]<sup>+</sup> 312.15914; found 312.15942.

(-)-tert-Butyl (2*S*,3*R*)-3-{[tert-Butyl(dimethyl)silyl]oxy}-6-oxo-2-[(trityloxy)methyl]-3,6-dihydropyridine-1(2*H*)-carboxylate (14): *N*-Methylimidazole (0.25 mg, 3.03 mmol), iodine (0.51 mg, 2.02 mmol), and TBSCl (0.16 mg, 1.06 mmol) were consecutively added to a solution of trans-6d (491 mg, 1.01 mmol) in  $CH_2Cl_2$  (5 mL) at 0 °C. The mixture was allowed to reach room temp. and

was stirred for 2 h whereupon TLC indicated full conversion [petroleum ether/ethyl acetate, 2:1;  $R_f = 0.18$  (6d) and  $R_f = 0.56$  (14); KMnO<sub>4</sub>]. The solution was diluted with ethyl acetate (10 mL), and the resulting mixture was washed with saturated aqueous Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> solution (20 mL) until the organic layer was colorless. The aqueous layer was extracted with ethyl acetate ( $3 \times 25$  mL), and the combined organic phases were washed with brine (10 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, from 30:1 to 4:1) to yield 14 (551 mg, 91%) as a colorless foam.  $[a]_{D}^{20} = -57$  (c = 1.72, CHCl<sub>3</sub>); 98% ee. <sup>1</sup>H NMR (300 MHz,  $CDCl_3$ ):  $\delta = 0.12, 0.17 (2 \text{ s}, 6 \text{ H}, \text{OTBS}), 0.90 (\text{s}, 9 \text{ H}, \text{OTBS}), 1.49$ [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 2.94 (dd, J = 9.2, 9.2 Hz, 1 H, OCH<sub>a</sub>H<sub>b</sub>), 3.35  $(dd, J = 9.0, 4.9 Hz, 1 H, OCH_aH_b), 4.39 (dd, J = 5.9, 1.5 Hz, 1$ H, 3-H), 4.66–4.71 (m, 1 H, 2-H), 5.84 (d, J = 9.5 Hz, 1 H, 5-H), 6.33 (ddd, J = 9.7, 5.7, 1.5 Hz, 1 H, 4-H), 7.21–7.44 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = -4.56$ , -4.25 (2 g, OTBS), 18.19 (s, OTBS), 25.82 (3 q, OTBS), 28.10 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 61.05 (d, C-2), 62.81 (d C-3), 62.96 (t, C-1'), 83.05 [s, C(CH<sub>3</sub>)<sub>3</sub>], 87.29 [s, C(Ph)<sub>3</sub>], 127.10 (d, C-5), 127.32 (3 d, C-Ar), 128.02 (6 d, C-Ar), 128.66 (6 d, C-Ar), 138.99 (d, C-4), 143.51 (3 s, C-Ar), 151.75 [s, COOC(CH<sub>3</sub>)<sub>3</sub>], 162.46 (s, C-6) ppm. HRMS (ESI+): calcd. for C<sub>36</sub>H<sub>45</sub>NNaO<sub>5</sub>Si<sup>+</sup> [M + Na]<sup>+</sup> 622.29.59; found 622.2957.

(+)-(4Z)-2-[(tert-Butoxycarbonyl)amino]-3-O-[tert-butyl(dimethyl)silyl]-2,4,5-trideoxy-1-O-trityl-D-erythro-hex-4-enitol (15): CeCl<sub>3</sub>·7  $H_2O$  (58 mg, 0.16 mmol) was added portionwise to a cooled (-10 °C), stirred solution of lactam 14 (85 mg, 0.14 mmol) in MeOH/H<sub>2</sub>O/CH<sub>2</sub>Cl<sub>2</sub> (10:1:0.05, v/v, 6 mL). After stirring for 5 min, NaBH<sub>4</sub> (16 mg, 0.43 mmol) was added in one portion. Vigorous gas evolution took place. After this had ceased, the mixture was warmed to -2 °C and stirred precisely at this temperature for 1 h whereupon TLC indicated complete conversion [petroleum ether/ ethyl acetate, 2:1;  $R_f = 0.56$  (14) and  $R_f = 0.40$  (15); KMnO<sub>4</sub>]. The solution was neutralized to pH = 7 by the addition of HCl (1 N solution), and the resulting solution was extracted with ethyl acetate  $(3 \times 15 \text{ mL})$ . The organic layers were washed with a saturated NaHCO<sub>3</sub> solution (5 mL) and brine (5 mL), dried with Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (petroleum ether/ethyl acetate, 4:1) to yield 15 (68 mg, 80%) as a colorless foam and 14 (7 mg, corrected yield 88%).  $[a]_{D}^{20} = +7.6 \ (c = 1.14, \text{ CHCl}_3); 98\% ee.$  <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta$  = -0.08, -0.04 (2 s, 6 H, OTBS), 0.75 (s, 9 H, OTBS), 1.44 [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 2.22 (br. s, 1 H, OH), 3.23-3.33 (m, 2 H, 1-H), 3.73 (br. s, 1 H, 2-H), 4.12-4.29 (m, 2 H, 6-H), 4.65–4.72 (m, 2 H, 3-H and NH), 5.45 (dd, J = 10.5, 9.1 Hz, 1 H, 4-H), 5.66 (ddd, J = 11.8, 6.2, 6.0 Hz, 1 H, 5-H), 7.21–7.44 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = -4.93, -4.26$  (2 q, OTBS), 18.10 (s, OTBS), 25.85 (3 q, OTBS), 28.58 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 56.31 (d, C-2), 58.99 (t, C-6), 62.13 (t, C-1), 69.42 (d, C-3), 79.65 [s, C(CH<sub>3</sub>)<sub>3</sub>], 86.99 [s, C(Ph)<sub>3</sub>], 127.21 (3 d, C-Ar), 127.96 (6 d, C-Ar), 128.90 (6 d, C-Ar), 130.29 (d, C-5), 133.47 (d, C-4), 143.98 (3 s, C-Ar), 155.91 [s, COOC(CH<sub>3</sub>)<sub>3</sub>] ppm. HRMS (ESI+): calcd. for  $C_{36}H_{49}NNaO_5Si^+$  [M + Na]<sup>+</sup> 626.3272; found 626.3271.

*tert*-Butyl ((1*S*,2*S*)-2-{[*tert*-Butyl(dimethyl)silyl]oxy}-3-oxo-1-[(trityloxy)methyl]-propyl)carbamate (16): A solution of 15 (45 mg, 0.075 mmol) and the indicator Sudan III in CH<sub>2</sub>Cl<sub>2</sub>/MeOH (1:1, v/ v) was exposed to ozone at -78 °C for 5 min and then treated with dimethylsulfide (35 µL) at -78 °C. After stirring for 10 min, the solution was warmed to room temp. The crude product was purified by flash column chromatography [petroleum ether (PE)/diethyl ether (EE), 4:1;  $R_{\rm f} = 0.32$  (15) and  $R_{\rm f} = 0.61$  (16); KMnO<sub>4</sub>] on silica gel (pentane/diethyl ether, 8:1) to give 16 (33 mg, 76%) as a colorless foam.  $[a]_{\rm D}^{20} = +21.5$  (c = 1.22, CHCl<sub>3</sub>). <sup>1</sup>H NMR

(300 MHz, CDCl<sub>3</sub>):  $\delta$  = -0.04 and 0.04 [2 s, 6 H, OSitBu-(CH<sub>3</sub>)<sub>2</sub>], 0.82 [s, 9 H, OSitBu(CH<sub>3</sub>)<sub>2</sub>], 1.41 [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 3.11– 3.24 (m, 2 H, 1'-H), 4.14–4.32 (m, 2 H, 2-H and 1-H), 4.50 (d, *J* = 8.8 Hz, 1 H, NH), 7.20–7.42 (m, 15 H, Ar), 9.61 (s, 1 H, CHO) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) = -5.10 and -4.46 {2 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 18.22 {s, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 25.84 {3 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 28.46 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 52.79 (d, C-1), 61.04 (t, C-1'), 78.22 (d, C-2), 79.99 [s, C(CH<sub>3</sub>)<sub>3</sub>], 87.82 [s, C(Ph)<sub>3</sub>], 127.25 (3 d, C-Ar), 128.02 (6 d, C-Ar), 128.80 (6 d, C-Ar), 143.54 (3s, C-Ar), 155.00 (s, COOtBu), 201.43 (d, CHO) ppm. HRMS (ESI+): calcd. for C<sub>34</sub>H<sub>45</sub>NNaO<sub>5</sub>Si<sup>+</sup> [M + Na]<sup>+</sup> 598.2959; found 598.2955.

tert-Butyl ((1S,2R,3E)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-[(trityloxy)methyl]-heptadec-3-en-1-yl)carbamate (17): A solution of KHMDS (0.5 M in toluene, 0.50 mL, 0.25 mmol) was added to a solution of 1-phenyl-5-tetradecylsulfonyl-1H-tetrazole (146 mg, 0.30 mmol) in dry DME (2.5 mL) under argon at -56 °C. The solution was stirred for 30 min as the color of the solution turned to yellow. A solution of aldehyde 16 (67 mg, 0.12 mmol) in DME (1.5 mL) was slowly added by cannula, and the mixture was stirred at -60 to -50 °C until TLC [PE/EE, 10:1;  $R_{\rm f} = 0.35$  (16) and  $R_{\rm f} =$ 0.53 (17); KMnO<sub>4</sub>] indicated full conversion of the aldehyde (4 h). Water was then added, and the mixture was warmed to room temp. After stirring for an additional 30 min, the mixture was extracted with Et<sub>2</sub>O, and the organic layers were washed with water, dried, and concentrated in vacuo. The residue was subjected to flash column chromatography on silica gel (pentane/diethyl ether, 20:1) to give 17 (56 mg, 64%, E/Z, 88:12). The Z/E isomers were separated by preparative HPLC [pentane/diethyl ether, 25:1;  $t_{\rm R} = 8.3$  (Z-17) and  $t_{\rm R} = 10.1 \text{ min } (E-17)$ ]. Data for (E)-17: Colorless oil.  $[a]_{\rm D}^{20} =$ +0.5 (c = 2.70, CHCl<sub>3</sub>). <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = -0.00$  [s, 6 H, OSitBu(CH<sub>3</sub>)<sub>2</sub>], 0.82 [s, 9 H, OSitBu(CH<sub>3</sub>)<sub>2</sub>], 0.91 (pseudo-t, J = 6.7 Hz, 3 H, 17-H), 1.29 (s, 22 H, 6-H–16-H), 1.47 [s, 9 H,  $C(CH_3)_3$ ], 1.93–1.97 (m, 2 H, 5-H), 3.22 (br. d, J = 4.8 Hz, 2 H, 1'-H), 3.80-3.87 (m, 1 H, 1-H), 4.32 (m, 1 H, 2-H), 4.59 (br. d, J = 8.5 Hz, 1 H, NH), 5.29 (dd, J = 15.4 Hz, J = 6.7 Hz, 1 H, 3-H), 5.60 (ddd, J = 15.6 Hz, J = 6.7 Hz, J = 6.7 Hz, 1 H, 4-H), 7.24– 7.48 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = -4.82$ and -4.04 {2 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 14.27 (q, C-17), 22.84 (t, C-16), 25.97 {3 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 28.61 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 29.31-29.85 (m, C-6-C-15), 32.08 {s, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 32.32 (t, C-5), 55.73 (d, C-1), 62.37 (t, C-1'), 73.94 (d, C-2), 79.01 [s, C(CH<sub>3</sub>) 3], 86.75 [s, C(Ph)3], 127.07 (3 d, C-Ar), 127.87 (6 d, C-Ar), 128.91 (6 d, C-Ar), 129.78 (d, C-3), 133.08 (d, C-4), 144.14 (3 s, C-Ar), 155.69 (s, COOtBu) ppm. HRMS (ESI+): calcd. for C<sub>48</sub>H<sub>73</sub>NNaO<sub>4</sub>Si<sup>+</sup> [M + Na]<sup>+</sup> 778.5201; found 778.5204. Data for (Z)-17: Colorless oil. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta = -0.07$  and -0.05 [2s, 6 H, OSitBu(CH<sub>3</sub>)<sub>2</sub>], 0.75 [s, 9 H, OSitBu(CH<sub>3</sub>)<sub>2</sub>], 0.88 (pseudo-t, J = 6.5 Hz, 3 H, H-17), 1.26 (s, 22 H, 6-H–16-H), 1.44 [s, 9 H, C(CH<sub>3</sub>)<sub>3</sub>], 1.94–2.12 (m, 2 H, 5-H), 3.20–3.31 (br. d, 2 H, 1'-H), 3.68-3.78 (m, 1 H, 1-H), 4.58-4.69 (m, 2 H, 2-H and NH), 5.23 (dd, J = 11.0 Hz, J = 8.6 Hz, 1 H, 3-H), 5.37 (ddd, J =11.4 Hz, J = 7.2 Hz, J = 7.2 Hz, 1 H, 4-H), 7.18–7.46 (m, 15 H, Ar) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta$  = -4.86 and -4.10 {2 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 14.27 (q, C-17), 22.85 (t, C-16), 25.92 {3 q, OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>}, 28.64 [3 q, C(CH<sub>3</sub>)<sub>3</sub>], 29.51–30.09 {m, C-6– C-15 and OSi[C(CH<sub>3</sub>)<sub>3</sub>](CH<sub>3</sub>)<sub>2</sub>, 32.08 (t, C-5), 55.82 (d, C-1), 62.35 (t, C-1'), 69.44 (d, C-2), 77.36 [s, C(CH<sub>3</sub>)<sub>3</sub>], 86.88 [s, C(Ph)<sub>3</sub>], 127.10 (3 d, C-Ar), 127.88 (6 d, C-Ar), 128.96 (6 d, C-Ar), 130.64 (d, C-3), 131.88 (d, C-4), 144.13 (3 s, C-Ar), 155.63 (s, COOtBu) ppm. HRMS (ESI+): calcd. for C<sub>48</sub>H<sub>73</sub>NNaO<sub>4</sub>Si<sup>+</sup> [M + Na]<sup>+</sup> 778.5201; found 778.5204.

(2*S*,3*R*,4*E*)-2-Aminooctadec-4-ene-1,3-diol [(-)-D-*erythro*-Sphingosine, 18]: TFA (1 mL) was added to a solution of (*E*)-17 (41 mg, 0.05 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL), and the resulting yellow solution was stirred at room temp. for 2 h. The solvent was removed under reduced pressure, and the residual ammonium salt was dissolved in MeOH and subjected to an ion-exchange column (Dowex 50Wx8, H<sup>+</sup> form) that was eluted with MeOH (20 mL), NH<sub>3</sub> (4 m in MeOH, 30 mL), and CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NEt<sub>3</sub> (8:1:0.01, 40 mL) to give 18 (7 mg, 40%) as white plates. Analytical data were in accordance with the literature.<sup>[27]</sup>  $[a]_{D}^{20} = -2.4$  (c = 0.90, CHCl<sub>3</sub>); ref.<sup>[27]</sup>  $[a]_{D}^{20} = -1.6 \ (c = 0.7, \text{ CHCl}_3)$ . <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>):  $\delta =$ 0.88 (t, J = 6.8 Hz, 3 H, 18-H), 1.26 (s, 22 H, 7-H–17-H), 2.04– 2.06 (m, 2 H, 6-H), 2.80–2.99 (2 br. s, 5 H, NH<sub>2</sub>, 2 OH, and 2-H), 3.64-3.74 (m, 2 H, 1-H), 4.14 (br. s, 1 H, 3-H), 5.46 (dd, J =14.8 Hz, J = 5.7 Hz, 1 H, 4-H), 5.77 (ddd, J = 15.1 Hz, J = 6.1 Hz, J = 6.1 Hz, 1 H, 5-H) ppm. <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>):  $\delta = 14.27$ (q, C-18), 22.85 (t, C-17), 29.33, 29.45, 29.52, 29.67, 29.80-29.86 (5 t), 32.08 (all t, C-7-C-16), 32.51 (t, C-6), 56.45 (d, C-2), 62.21 (t, C-1), 74.62 (d, C-3), 128.80 (d, C-4), 134.96 (d, C-5) ppm. HRMS (ESI+): calcd. for C<sub>18</sub>H<sub>38</sub>NO<sub>2</sub><sup>+</sup> [M + H]<sup>+</sup> 300.2897; found 300.2897.

**Supporting Information** (see footnote on the first page of this article): Additional synthetic route to **18**, general procedures for the Ir-catalyzed allylic substitution, HPLC data, and <sup>1</sup>H NMR spectra of all compounds.

#### Acknowledgments

This work was supported by the Deutsche Forschungsgemeinschaft (DFG) (SFB 623) and the Fonds der Chemischen Industrie. The authors thank Dr. Frank Rominger and his team for the X-ray crystal structure analyses.

- [1] G. M. Strunz, J. A. Findlay, in: *The Alkaloids* (Ed.: A. Brossi), Academic Press, New York, **1985**, vol. 26, p. 89–183.
- [2] a) P. Compain, O. R. Martin (Eds.), *Iminosugars*, Wiley, Chichester, UK, 2007; b) A. B. Hughes, A. J. Rudge, *Nat. Prod. Rep.* 1994, 11, 135–162; c) B. Winchester, G. W. J. Fleet, *Glycobiology* 1992, 2, 199–210.
- [3] T. Harrison, B. J. Williams, C. J. Swain, R. G. Ball, *Bioorg. Med. Chem. Lett.* 1994, 4, 2545–2550.
- [4] Q. Khuong-Huu, G. Ratle, X. Monseur, R. Goutarel, *Bull. Soc. Chim. Belg.* **1972**, 425–442.
- [5] P. L. van Giersbergen, J. Dingemanse, J. Clin. Pharmacol. 2007, 47, 1277–1282.
- [6] For reviews, see: a) M. A. Wijdeven, J. Willemsen, F. P. J. T. Rutjes, *Eur. J. Org. Chem.* 2010, 2831–2844; b) J. Cossy, *Chem. Rec.* 2005, 5, 70–80; c) M. G. P. Buffat, *Tetrahedron* 2004, 60, 1701–1729; d) F.-X. Felpin, J. Lebreton, *Eur. J. Org. Chem.* 2003, 3693–3712.
- [7] a) G. W. Fleet, N. G. Ramsden, D. R. Witty, *Tetrahedron* 1989, 45, 319–326; b) H. Yokoyama, K. Otaya, H. Kobayashi, M. Miyazawa, S. Yamaguchi, Y. Hirai, Org. Lett. 2000, 2, 2427–2429; c) I. Izquierdo Cubero, M. T. P. Lopez-Espinosa, A. C. Richardson, M. D. Suarez Ortega, *Carbohydr. Res.* 1993, 242, 109–118; d) A. De Raadt, A. E. Stuetz, *Tetrahedron Lett.* 1992, 33, 189–192; e) R. C. Bernotas, B. Ganem, *Tetrahedron Lett.* 1985, 26, 1123–1126.
- [8] a) I. Ojima, Pure Appl. Chem. 2002, 74, 159–166; b) S. R. V. Kandula, P. Kumar, Tetrahedron 2006, 62, 9942–9948; c) K. Takahashi, H. Nakano, R. Fujita, Tetrahedron Lett. 2005, 46, 8927–8930; d) G. Kim, N. Kim, Tetrahedron Lett. 2007, 48, 4481–4483.
- [9] For selected examples, see: a) M. Gärtner, R. Weihofen, G. Helmchen, *Chem. Eur. J.* 2011, *17*, 7605–7622; b) A. Farwick, G. Helmchen, *Adv. Synth. Catal.* 2010, *352*, 1023–1032; c) A. Farwick, G. Helmchen, *Org. Lett.* 2010, *12*, 1108–1111; d) P. Dübon, A. Farwick, G. Helmchen, *Synlett* 2009, *9*, 1413–1416;



e) C. Gnamm, C. M. Krauter, K. Brödner, G. Helmchen, *Chem. Eur. J.* **2009**, *15*, 2050–2054; f) C. Gnamm, K. Brödner, C. M. Krauter, G. Helmchen, *Chem. Eur. J.* **2009**, *15*, 10514– 10532.

- [10] For reviews, see: a) G. Helmchen, in: Iridium Complexes in Organic Synthesis (Eds.: L. A. Oro, C. Claver), Wiley-VCH, Weinheim, Germany, 2009, p. 211–250; b) G. Helmchen, A. Dahnz, P. Dübon, M. Schlewies, R. Weihofen, Chem. Commun. 2007, 675–691; c) R. Takeuchi, S. Kezuka, Synthesis 2006, 3349–3366; d) H. Miyabe, Y. Takemoto, Synlett 2005, 1641–1655; e) J. F. Hartwig, L. M. Stanley, Acc. Chem. Res. 2010, 43, 1461–1475; f) W.-B. Liu, J.-B. Xia, S.-L. You, Top. Organomet. Chem. 2012, 38, 155–208; g) P. Tosatti, A. Nelson, S. P. Marsden, Org. Biomol. Chem. 2012, 10, 3147–3163.
- [11] a) G. Franck, K. Brödner, G. Helmchen, Org. Lett. 2010, 12, 3886–3889; b) M. Gärtner, M. Jäkel, M. Achatz, C. Sonnenschein, O. Tverskoy, G. Helmchen, Org. Lett. 2011, 13, 2810–2813; c) J. G. Knight, K. Tchabanenko, Tetrahedron 2003, 59, 281–286; d) J. Robertson, E. Abdulmalek, Tetrahedron Lett. 2009, 50, 3516–3518.
- [12] J. G. Knight, K. Tchabanenko, *Tetrahedron* **2002**, *58*, 6659–6664.
- [13] a) T. Ohmura, J. F. Hartwig, J. Am. Chem. Soc. 2002, 124, 15164–15165; b) C. Welter, O. Koch, G. Lipowsky, G. Helmchen, Chem. Commun. 2004, 896–897; c) C. Welter, A. Dahnz, B. Brunner, S. Streiff, P. Dübon, G. Helmchen, Org. Lett. 2005, 7, 1239–1242; d) T. Nemoto, T. Sakamoto, T. Matsumoto, Y. Hamada, Tetrahedron Lett. 2006, 47, 8737–8740; e) D. Polet, A. Alexakis, K. Tissot-Croset, C. Corminboeuf, K. Ditrich, Chem. Eur. J. 2006, 12, 3596–3609; f) C. Gnamm, G. Franck, N. Miller, T. Stork, K. Brödner, G. Helmchen, Synthesis 2008, 3331–3350; g) S. Spiess, C. Welter, G. Franck, J.-P. Taquet, G. Helmchen, Angew. Chem. 2008, 120, 7764; Angew. Chem. Int. Ed. 2008, 47, 7652–7655.
- [14] a) R. Weihofen, O. Tverskoy, G. Helmchen, Angew. Chem.
  2006, 118, 5673–5676; Angew. Chem. Int. Ed. 2006, 45, 5546–5549; b) O. V. Singh, H. Han, Tetrahedron Lett. 2007, 48, 7094–7098; c) M. J. Pouy, A. Leitner, D. J. Weix, S. Ueno, J. F. Hartwig, Org. Lett. 2007, 9, 3949–3952; d) D. J. Weix, D. Markovic, M. Ueda, J. F. Hartwig, Org. Lett. 2009, 11, 2944–2947.
- [15] S. Spiess, C. Berthold, R. Weihofen, G. Helmchen, Org. Biomol. Chem. 2007, 5, 2357–2360.
- [16] S. T. Madrahimov, D. Marcovic, J. F. Hartwig, J. Am. Chem. Soc. 2009, 131, 7228–7229, see also Supporting Information, p. 4.

- [17] We employed the conditions of Knight et al.<sup>[11c]</sup> with the exception that the sensitive epoxide was not purified, that is, after aqueous workup, the elimination was carried out with the crude epoxide.
- [18] Low yield and poor diastereoselectivity (*syn/anti*, 3:1) were obtained under a variety of epoxidation conditions with the corresponding lactones (F. Bächle, unpublished results).
- [19] M.-R. Tsai, B.-F. Chen, C.-C. Cheng, N.-C. Chang, J. Org. Chem. 2005, 70, 1780–1785.
- [20] P.-Q. Huang, L.-X. Liu, B.-G. Wei, Y.-P. Ruan, Org. Lett. 2003, 5, 1927–1929.
- [21] For a review of sphingosine syntheses, see: P. M. Koskinen, A. M. P. Koskinen, *Synthesis* **1998**, 1075–1091.
- [22] A. Bartoszewicz, M. Kalek, J. Nilsson, R. Hiresova, J. Stawinski, Synlett 2008, 37–40.
- [23] a) J. Marin, A. Violette, J.-P. Briand, G. Guichard, *Eur. J. Org. Chem.* 2004, 3027–3039; b) J. Marin, C. Didierjean, A. Aubry, J.-R. Casimir, J.-P. Briand, G. Guichard, *J. Org. Chem.* 2004, 69, 130–141; c) J. Marin, J.-P. Briand, G. Guichard, *Eur. J. Org. Chem.* 2008, 1005–1012.
- [24] A. L. Gemal, J.-L. Luche, J. Am. Chem. Soc. 1981, 103, 5454– 5459.
- [25] P. R. Blackmore, W. J. Cole, P. J. Kocienski, A. Morley, Synlett 1998, 26–28.
- [26] F. Compostella, L. Franchini, L. Panza, D. Prosperi, F. Ronchetti, *Tetrahedron* 2002, 58, 4425–4428.
- [27] a) J. Llaveria, Y. Díaz, M. I. Matheu, S. Castillón, Org. Lett.
   2009, 11, 205–208; b) F. Sarmientos, G. Schwarzmann, K. Sandhoff, Eur. J. Biochem. 1985, 146, 59–64.
- [28] Another approach (not shown) involved allylic substitution of the acetate of 15 by an organocuprate reagent. This furnished only a moderate overall yield of 18 (3% in 12 linear steps). Experimental procedures are described in the Supporting Information.
- [29] a) Y. Sasaki, K. Yamaguchi, T. Tsuji, A. Shigenaga, N. Fujii, A. Otaka, *Tetrahedron Lett.* 2007, 48, 3221–3224, see also the Supporting Information; b) A. Niida, M. Mizumoto, T. Narumi, E. Inokuchi, S. Oishi, H. Ohno, A. Otaka, K. Kitaura, N. Fujii, *J. Org. Chem.* 2006, 71, 4118–4129. The optical rotations of 5a and *trans*-6a that are given in these publications are too low. This is most likely because of the partial racemization of the intermediary aldehydes that are derived from alanine methyl ester.

Received: March 26, 2013 Published Online: July 2, 2013